AB 54: Access to Safe Abortion Care Act.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2025-07-01
Current Status:
In Progress
(2026-08-30: Ordered to inactive file at the request of Senator McNerney.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law sets forth provisions, under the California Constitution, regarding the fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.
This bill, the Access to Safe Abortion Care Act, would make legislative findings about medication abortion, with a focus on use of the drugs mifepristone and misoprostol. Under the bill, the Legislature would reaffirm that it has been, and would continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
The bill would set forth provisions regarding the lack of civil or criminal liability, or professional disciplinary action, for accessing or administering brand name or generic mifepristone or misoprostol, among other certain conduct, or any drug used for medication abortion that is lawful under the laws of the state, on or after January 1, 2020, with this provision applied retroactively, as specified.
The bill would make its provisions severable.
Existing law sets forth provisions, under the California Constitution, regarding the fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.
This bill, the Access to Safe Abortion Care Act, would make legislative findings about medication abortion, with a focus on use of the drugs mifepristone and misoprostol. The bill would state the intent of the Legislature to enact legislation that would ensure access to medication abortion. Under the bill, the Legislature would reaffirm that it has been, and would continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
The bill would set forth provisions regarding the lack of civil or criminal liability, or professional disciplinary action, for accessing or administering mifepristone or misoprostol, among other certain conduct, on or after January 1, 2020, with this provision applied retroactively, as specified.
The bill would make its provisions severable.
Existing law sets forth provisions, under the California Constitution, regarding the fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.
This bill, the Access to Safe Abortion Care Act, would make legislative findings about medication abortion, with a focus on use of the drugs mifepristone and misoprostol. The bill would state the intent of the Legislature to enact legislation that would ensure access to medication abortion.
The Legislature finds and declares all of the following:
(a)In 1973, the United States Supreme Court recognized a federal constitutional right to an abortion in Roe v. Wade (1973) 410 U.S. 113. For nearly 50 years, and through numerous challenges, the federal courts consistently upheld this fundamental right. However, in 2022, the United States Supreme Court reversed course. In Dobbs v. Jackson Womens Health Organization (2022) 597 U.S. 215, the Court threw out decades of precedent, overruled Roe, and concluded that there was no federal constitutional right to an abortion. In reaching that conclusion, the Court return[ed] the authority to regulate abortion to the people and their elected representatives (id. at 302).
(b)Both before and after the Dobbs decision was announced, California enacted numerous measures to protect the right to an abortion at the state level. Chief among these is Section 1.1 of Article I of the California Constitution, which states that individuals in California have a constitutional right to choose to have an abortion.
(c)Californias decision to protect access to abortion as a matter of both individual rights and sound public policy is consistent with the promise of the Dobbs decision that abortion would be entrusted to the states and the normal political processes. However, in the wake of Dobbs, there are numerous threats to access to abortion care and reproductive rights, even in California. In particular, an ongoing court case, Missouri et al. v. U.S. FDA et al., Case No. 2:22-cv-00223-Z (N.D. Tex), threatens to upend access to mifepristone.
(d)In 2000, the United States Food and Drug Administration (FDA) approved mifepristone for use in the termination of pregnancy. In April 2019, the FDA approved a generic version of mifepristone.
(e)Mifepristone is usually used in combination with misoprostol to terminate a pregnancy. Misoprostol can also be used on its own to terminate a pregnancy. When mifepristone and misoprostol are used in combination, or when misoprostol is used alone to terminate a pregnancy, this is referred to as a medication abortion, to distinguish it from a procedural abortion.
(f)Today, providers and researchers estimate that over 60 percent of all abortions in the United States are done using medication abortion.
(g)With over 20 years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4-percent risk of major complications, and a mortality rate of only 0.00064 percent. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a 0.0049-percent mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the United States has an overall maternal mortality rate of 0.0329 percent.
(h)Instrumentalities of the State of California regularly acquire and provide mifepristone and misoprostol. The five medical centers owned and operated by the University of California, for instance, all routinely acquire and use mifepristone and misoprostol for their patients in a variety of contexts.
(i)Pursuant to the College Student Right to Access Act, each public university student health center (including at the University of California and California State University systems) is required to offer abortion by medication techniques onsite.
(j)The widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the State of California, including safeguarding the health and welfare of Californians as a safe, effective, and accessible means of terminating a pregnancy, and by providing medical providers with safe and effective options to treat their patients under a wide variety of circumstances.
SEC. 2.Chapter 25 (commencing with Section 27050) is added to Division 20 of the Health and Safety Code, to read:25.Access to Safe Abortion Care Act27050.This chapter shall be known, and may be cited, as the Access to Safe Abortion Care Act.
27051.(a)Consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
(b)A manufacturer, distributor, authorized health care provider, pharmacist, or individual shall not be subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance with this chapter. This subdivision shall be applied retroactively to January 1, 2020.
27052.The provisions of this chapter are severable. If any provision of this chapter or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
The Legislature finds and declares all of the following:
(a)In 1973, the United States Supreme Court recognized a federal constitutional right to an abortion in Roe v. Wade (1973) 410 U.S. 113. For nearly 50 years, and through numerous challenges, the federal courts consistently upheld this fundamental right. However, in 2022, the United States Supreme Court reversed course. In Dobbs v. Jackson Womens Health Organization (2022) 597 U.S. 215, the Court threw out decades of precedent, overruled Roe, and concluded that there was no federal constitutional right to an abortion. In reaching that conclusion, the Court return[ed] the authority to regulate abortion to the people and their elected representatives (id. at 302).
(b)Both before and after the Dobbs decision was announced, California enacted numerous measures to protect the right to an abortion at the state level. Chief among these is Section 1.1 of Article I of the California Constitution, which states that individuals in California have a constitutional right to choose to have an abortion.
(c)Californias decision to protect access to abortion as a matter of both individual rights and sound public policy is consistent with the promise of the Dobbs decision that abortion would be entrusted to the states and the normal political processes. However, in the wake of Dobbs, there are numerous threats to access to abortion care and reproductive rights, even in California. In particular, an ongoing court case, Missouri et al. v. U.S. FDA et al., Case No. 2:22-cv-00223-Z (N.D. Tex), threatens to upend access to mifepristone.
(d)In 2000, the United States Food and Drug Administration (FDA) approved mifepristone for use in the termination of pregnancy. In April 2019, the FDA approved a generic version of mifepristone.
(e)Mifepristone is usually used in combination with misoprostol to terminate a pregnancy. Misoprostol can also be used on its own to terminate a pregnancy. When mifepristone and misoprostol are used in combination, or when misoprostol is used alone to terminate a pregnancy, this is referred to as a medication abortion, to distinguish it from a procedural abortion.
(f)Today, providers and researchers estimate that over 60 percent of all abortions in the United States are done using medication abortion.
(g)With over 20 years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4-percent risk of major complications, and a mortality rate of only 0.00064 percent. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a 0.0049-percent mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the United States has an overall maternal mortality rate of 0.0329 percent.
(h)Instrumentalities of the State of California regularly acquire and provide mifepristone and misoprostol. The five medical centers owned and operated by the University of California, for instance, all routinely acquire and use mifepristone and misoprostol for their patients in a variety of contexts.
(i)Pursuant to the College Student Right to Access Act, each public university student health center (including at the University of California and California State University systems) is required to offer abortion by medication techniques onsite.
(j)The widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the State of California, including safeguarding the health and welfare of Californians as a safe, effective, and accessible means of terminating a pregnancy, and by providing medical providers with safe and effective options to treat their patients under a wide variety of circumstances.
SEC. 2.Chapter 25 (commencing with Section 27050) is added to Division 20 of the Health and Safety Code, to read:25.Access to Safe Abortion Care Act27050.This chapter shall be known, and may be cited, as the Access to Safe Abortion Care Act.
27051.(a)Consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
(b)A manufacturer, distributor, authorized health care provider, pharmacist, or individual shall not be subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance with this chapter. This subdivision shall be applied retroactively to January 1, 2020.
27052.The provisions of this chapter are severable. If any provision of this chapter or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SECTION 1.This act shall be known, and may be cited, as the Access to Safe Abortion Care Act.SEC. 2.The Legislature finds and declares all of the following:(a)Consistent with Section 1.1 of Article I of the California Constitution, individuals in the State of California have a constitutional right to choose to have an abortion.(b)In 2000, the federal Food and Drug Administration (FDA) approved mifepristone for use in the termination of pregnancy through 7 weeks of gestation, and extended its use to 10 weeks of gestation in 2016. In April 2019, the FDA approved a generic version of mifepristone.(c)Mifepristone is usually used in combination with a second drug, called misoprostol, to terminate a pregnancy. Misoprostol can also be used on its own to terminate a pregnancy. When mifepristone and misoprostol are used in combination, or when misoprostol is used alone to terminate a pregnancy, this is referred to as a medication abortion, to distinguish it from a procedural abortion.(d)Today, providers and researchers estimate that over 60 percent of all abortions in the United States are done using medication abortion.(e)With over 20 years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4 percent risk of major complications, and a mortality rate of only 0.00064 percent. To put these figures in perspective, this is lower than the mortality rate associated with sildenafil, which carries a 0.0049 percent mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the United States has an overall maternal mortality rate of 0.0329 percent.(f)Mifepristone and misoprostol are widely used for the outpatient treatment of miscarriage. Medical providers utilize mifepristone and misoprostol in these instances to guard against many of the medical risks associated with miscarriage. During a miscarriage, a patient is at increased risk of infection and hemorrhage, which can lead to severe complications, permanent disability and loss of organ function, and, in extreme cases, death. The longer a miscarriage lasts, the greater the risk of these complications. A patient may also fail to fully pass the deceased fetus, placenta, or other products of conception, prolonging the process and increasing these risks. Mifepristone and misoprostol help to rapidly and completely empty the contents of a patients uterus, and thus mitigate these risks.(g)There are a number of conditions, including, but not limited to, PPROM or dilation of the cervix, which, when they occur before the point of viability, result in what doctors refer to as an inevitable miscarriage; though the fetus may still be alive, it has no chance of surviving outside the womb or long enough to reach viability. Because the risk of serious and potentially life-threatening complications increases as the pregnancy progresses, standard treatment in these tragic situations frequently involves administering mifepristone and misoprostol to immediately terminate the pregnancy.(h)From a medical perspective, there is no difference between the case of using mifepristone and misoprostol to terminate a nonviable pregnancy, using those drugs to treat a miscarriage, or using them to terminate a viable pregnancy. In all cases, the same drugs are administered, and the same biological processes ensue.(i)Misoprostol is also used to induce labor for patients with viable pregnancies when, for instance, a patients pregnancy is going too far past term (41 or 42 weeks in most cases), or when a late-developing complication, such as hypertension or preeclampsia, makes an earlier delivery the safest option.(j)Instrumentalities of the State of California regularly acquire and provide mifepristone and misoprostol. The five medical centers owned and operated by the University of California, for instance, all routinely acquire and use mifepristone and misoprostol for their patients in a variety of contexts.(k)Pursuant to the College Student Right to Access Act, each public university student health center (including at the University of California and California State University systems) is required to offer abortion by medication techniques onsite.(l)The widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the State of California, including safeguarding the health and welfare of Californians as a safe, effective, and convenient means of terminating a pregnancy, and by providing medical providers with safe and effective options to treat their patients in a wide variety of circumstances.(m)There are emerging threats to the availability of mifepristone and misoprostol, and California may not be able to guarantee a continued supply. Previously, Governor Newsom implemented a plan to stockpile doses of misoprostol. While this effort was successful, the Legislature finds that the state needs to renew its stockpile to ensure that Californians can continue to exercise their constitutional rights.SEC. 3.It is the intent of the Legislature to enact legislation that would ensure access to medication abortion. REVISIONS: HeadingLine 3.This act shall be known, and may be cited, as the Access to Safe Abortion Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)Consistent with Section 1.1 of Article I of the California Constitution, individuals in the State of California have a constitutional right to choose to have an abortion.
(b)In 2000, the federal Food and Drug Administration (FDA) approved mifepristone for use in the termination of pregnancy through 7 weeks of gestation, and extended its use to 10 weeks of gestation in 2016. In April 2019, the FDA approved a generic version of mifepristone.
(c)Mifepristone is usually used in combination with a second drug, called misoprostol, to terminate a pregnancy. Misoprostol can also be used on its own to terminate a pregnancy. When mifepristone and misoprostol are used in combination, or when misoprostol is used alone to terminate a pregnancy, this is referred to as a medication abortion, to distinguish it from a procedural abortion.
(d)Today, providers and researchers estimate that over 60 percent of all abortions in the United States are done using medication abortion.
(e)With over 20 years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4 percent risk of major complications, and a mortality rate of only 0.00064 percent. To put these figures in perspective, this is lower than the mortality rate associated with sildenafil, which carries a 0.0049 percent mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the United States has an overall maternal mortality rate of 0.0329 percent.
(f)Mifepristone and misoprostol are widely used for the outpatient treatment of miscarriage. Medical providers utilize mifepristone and misoprostol in these instances to guard against many of the medical risks associated with miscarriage. During a miscarriage, a patient is at increased risk of infection and hemorrhage, which can lead to severe complications, permanent disability and loss of organ function, and, in extreme cases, death. The longer a miscarriage lasts, the greater the risk of these complications. A patient may also fail to fully pass the deceased fetus, placenta, or other products of conception, prolonging the process and increasing these risks. Mifepristone and misoprostol help to rapidly and completely empty the contents of a patients uterus, and thus mitigate these risks.
(g)There are a number of conditions, including, but not limited to, PPROM or dilation of the cervix, which, when they occur before the point of viability, result in what doctors refer to as an inevitable miscarriage; though the fetus may still be alive, it has no chance of surviving outside the womb or long enough to reach viability. Because the risk of serious and potentially life-threatening complications increases as the pregnancy progresses, standard treatment in these tragic situations frequently involves administering mifepristone and misoprostol to immediately terminate the pregnancy.
(h)From a medical perspective, there is no difference between the case of using mifepristone and misoprostol to terminate a nonviable pregnancy, using those drugs to treat a miscarriage, or using them to terminate a viable pregnancy. In all cases, the same drugs are administered, and the same biological processes ensue.
(i)Misoprostol is also used to induce labor for patients with viable pregnancies when, for instance, a patients pregnancy is going too far past term (41 or 42 weeks in most cases), or when a late-developing complication, such as hypertension or preeclampsia, makes an earlier delivery the safest option.
(j)Instrumentalities of the State of California regularly acquire and provide mifepristone and misoprostol. The five medical centers owned and operated by the University of California, for instance, all routinely acquire and use mifepristone and misoprostol for their patients in a variety of contexts.
(k)Pursuant to the College Student Right to Access Act, each public university student health center (including at the University of California and California State University systems) is required to offer abortion by medication techniques onsite.
(l)The widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the State of California, including safeguarding the health and welfare of Californians as a safe, effective, and convenient means of terminating a pregnancy, and by providing medical providers with safe and effective options to treat their patients in a wide variety of circumstances.
(m)There are emerging threats to the availability of mifepristone and misoprostol, and California may not be able to guarantee a continued supply. Previously, Governor Newsom implemented a plan to stockpile doses of misoprostol. While this effort was successful, the Legislature finds that the state needs to renew its stockpile to ensure that Californians can continue to exercise their constitutional rights.
SEC. 3.It is the intent of the Legislature to enact legislation that would ensure access to medication abortion.
CORRECTIONS: HeadingLine 2.|
Date
|
Status
|
|---|---|
| Aug 30, 2026 | Ordered to inactive file at the request of Senator McNerney. |
| Aug 25, 2026 | Read second time. Ordered to third reading. |
| Aug 24, 2026 | Ordered to second reading. |
| Aug 24, 2026 | From inactive file. |
| Sep 10, 2025 | Ordered to inactive file at the request of Senator Umberg. |
| Aug 20, 2025 | Read second time. Ordered to third reading. |
| Aug 19, 2025 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| Jul 16, 2025 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (July 15). Re-referred to Com. on APPR. |
| Jul 1, 2025 | Read second time and amended. Re-referred to Com. on JUD. |
| Jun 30, 2025 | From committee: Amend, and do pass as amended and re-refer to Com. on JUD. (Ayes 9. Noes 1.) (June 25). |
| Jun 11, 2025 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| May 21, 2025 | Referred to Coms. on HEALTH and JUD. |
| May 13, 2025 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 12, 2025 | Read third time. Passed. Ordered to the Senate. (Ayes 61. Noes 10. Page 1517.) |
| May 8, 2025 | Read second time. Ordered to third reading. |
| May 7, 2025 | From committee: Do pass. (Ayes 11. Noes 1.) (May 7). |
| Apr 30, 2025 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 1.) (April 29). Re-referred to Com. on APPR. |
| Apr 30, 2025 | Coauthors revised. |
| Apr 9, 2025 | From committee: Do pass and re-refer to Com. on JUD. (Ayes 12. Noes 0.) (April 8). Re-referred to Com. on JUD. |
| Apr 9, 2025 | Coauthors revised. |
| Mar 18, 2025 | Re-referred to Com. on HEALTH. |
| Mar 17, 2025 | Referred to Coms. on HEALTH and JUD. |
| Mar 17, 2025 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Dec 3, 2024 | From printer. May be heard in committee January 2. |
| Dec 2, 2024 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jul 15, 2025 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Judiciary |
Passed |
|
| Jun 25, 2025 | Do pass as amended, but first amend, and re-refer to the Committee on [Judiciary] | Senate Standing Committee on Health |
Passed |
|
| May 12, 2025 | AB 54 Krell Assembly Third Reading | Assembly Floor |
Passed |
|
| May 7, 2025 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 29, 2025 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Judiciary |
Passed |
|
| Apr 8, 2025 | Do pass and be re-referred to the Committee on [Judiciary] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| All Above All | ** Support | |
| All Above All (co-source) | ** Support | |
| AMERICAN COLLEGE OF OBSTETRICIANS & GYNECOLOGISTS - DISTRICT IX | ** Support | |
| Attorney General Rob Bonta | ** Support | |
| Attorney General Rob Bonta (co- source) | ** Support | |
| Black Women For Wellness Action Project | ** Support | |
| Black Women for Wellness Action Project (co- source) | ** Support | |
| California Baptists for Biblical Values | ** Against | |
| California Civil Liberties Advocacy | ** Support | |
| California Commission on Status of Women and Girls | ** Support | |
| California Commission on Status of Women and Girls (co- source) | ** Support | |
| California Family Council | ** Against | |
| California Latinas for Reproductive Justice | ** Support | |
| California Latinas for Reproductive Justice (co- source) | ** Support | |
| California Medical Association | ** Support | |
| California Nurse Midwives Association | ** Support | |
| CALIFORNIA PRIMARY CARE ASSOCIATION ADVOCATES | ** Support | |
| California Teachers Association | ** Support | |
| California Women Lawyers | ** Support | |
| California Women's Law Center | ** Support | |
| Citizens for Choice | ** Support | |
| County Of Los Angeles | ** Support | |
| County of Los Angeles Board of Supervisors | ** Support | |
| Equality California | ** Support | |
| Essential Access Health | ** Support | |
| Essential Health Access | ** Support | |
| Essential Health Access (co- source) | ** Support | |
| Lighthouse Baptist Church | ** Against | |
| National Health Law Program | ** Support | |
| National Health Law Program (co- source) | ** Support | |
| NextGen California | ** Support | |
| One individual | ** Support | |
| One individual | ** Against | |
| Osteopathic Medical Board of California | ** Support | |
| Pacific Justice Institute Center for Public Policy | ** Against | |
| Planned Parenthood Affiliates Of California | ** Support | |
| Planned Parenthood Affiliates of California (co- source) | ** Support | |
| Reproductive Freedom for All California | ** Support | |
| Reproductive Freedom for All California (co- source) | ** Support | |
| San Francisco Bay Area Black & Jewish Coalition | ** Support | |
| Women’s Health Specialist’s | ** Support | |
| Women’s Liberation Front | ** Support |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 54 |
THIRD READING
Bill No: AB 54
Author: Krell (D) and Aguiar-Curry (D), et al.
Amended: 7/1/25 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 9-1, 6/25/25
AYES: Menjivar, Durazo, Gonzalez, Limón, Padilla, Richardson, Rubio, Weber Pierson, Wiener
NOES: Grove
NO VOTE RECORDED: Valladares
SENATE JUDICIARY COMMITTEE: 11-0, 7/15/25
AYES: Umberg, Allen, Arreguín, Ashby, Caballero, Durazo, Laird, Stern, Wahab, Weber Pierson, Wiener
NO VOTE RECORDED: Niello, Valladares
ASSEMBLY FLOOR: 61-10, 5/12/25 - See last page for vote
SUBJECT: Access to Safe Abortion Care Act
SOURCE: All Above All
Attorney General Rob Bonta
Black Women for Wellness Action Project
California Commission on Status of Women and Girls
California Latinas for Reproductive Justice
Essential Health Access
National Health Law Program
Planned Parenthood Affiliates of California
Reproductive Freedom for All California
DIGEST:
This bill prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state after January 1, 2020.
ANALYSIS:
Existing law:
- Establishes the Reproductive Privacy Act (RPA), which prohibits the state from denying or interfering with a woman’s right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the woman. [Health and Safety Code (HSC) §123460, et seq.]
- Prohibits a person who aids or assists a pregnant person in exercising their rights under RPA from being subject to civil or criminal liability or penalty, or otherwise being deprived of their rights, based solely on their actions to aid or assist a pregnant person in exercising their rights under RPA with the pregnant person's voluntary consent. [HSC §123467]
- Provides that a law of another state that authorizes a person to bring a civil action against a person or entity who does any of the following is contrary to the public policy of this state: receives or seeks an abortion; performs or induces an abortion; knowingly engages in conduct that aids or abets the performance or inducement of an abortion; or, attempts or intends to engage in the aforementioned conduct. [HSC §123467.5]
This bill:
- Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020, in accordance with state laws, applicable and accepted standards of care, and good faith compliance with this bill. Requires this bill to be applied retroactively to January 1, 2020.
- States that, consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
- Makes this bill’s provisions severable: if any provision or its application is held invalid, that invalidity is prohibited from affecting other provisions or applications that can be given effect without the invalid provision or application.
Comments
According to the author of this bill:
In 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. As former Chief Legal Counsel to Planned Parenthood, I fought federal efforts to eliminate access to reproductive care in the first Trump Administration. It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. This bill shields manufacturers, distributers, and health care providers from liability for providing medication abortion to Californians.
Background
Abortion. According to the Center for Diseases Control and Prevention (CDC), a legal induced abortion is defined as an intervention performed by a licensed clinician that is intended to terminate an ongoing pregnancy. Ending a pregnancy with medications is an option for women who are less than ten weeks pregnant and would like to have an abortion at home with a less invasive procedure. The CDC reports that 613,383 abortions were reported nationally from 48 reporting areas in 2022. From 2021 to 2022, the total number of abortions decreased 2%, and the number decreased 5% between 2013 and 2022. In 2022, women in their 20s accounted for more than half of abortions (56.5%). By contrast, adolescents under 15 years (0.2%) and women over 40 (3.6%) years accounted for the lowest percentages of abortions. In 2022, nearly all abortions (92.8%) were performed at or less than 13 weeks gestation. That year, the highest proportion of abortions were performed by early medication abortion at or less than nine weeks’ gestation (53.3%), followed by surgical abortion at or less than 13 weeks gestation (35.5%), surgical abortion at more than 13 weeks gestation (6.9%), and medication abortion at more than nine weeks gestation (4.3%). In 2021, the most recent year for which data was reviewed for pregnancy-related deaths, five women died as a result of complications from legal induced abortion.
California data. According to the Guttmacher Institute, 182,170 abortions were provided by clinicians in California in 2024, though not all those abortions were provided to state residents. In January 2025, there were an estimated 17,020 clinician-provided abortions, and that number was consistent with the previous six-month period (average of 15,000 abortions per month). Data for 2023, the first full year after the U.S. Supreme Court overturned Roe v. Wade, show that an estimated total of 179,120 clinician-provided abortions took place in California (an increase of 1.7%).
Medication abortion. According to a March 2024 Kaiser Family Foundation factsheet, medication abortion is a pregnancy termination protocol that involves taking two different drugs approved for use up to the first 10 weeks of pregnancy by the U.S. Food and Drug Administration (FDA). The World Health Organization has authorized use up to 12 weeks of pregnancy. Since the FDA first approved the drug in 2000, its use in the U.S. has grown. In 2023, 63% of abortions in the U.S. were medication abortions. The most common medication abortion regimen involves the use of two different medications: mifepristone and misoprostol. Mifepristone, also known as the abortion pill or RU-486, is sold under the brand name Mifeprex and through a generic manufactured by GenBioPro. Mifepristone works by blocking progesterone, a hormone essential to the development of a pregnancy, and prevents an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. A follow-up visit can be scheduled a week or two later to confirm that the pregnancy was terminated via ultrasound or blood test. The FDA has found that medication abortion is a safe and highly effective method of pregnancy termination. Medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and a mortality rate of 0.00064%. Telehealth can be used to expand access to abortion services in areas where the number of clinicians who provide that care is limited. Many patients, particularly those who live in rural communities, must travel long distances to obtain abortion services even in states where abortion is still permitted. Because the updated FDA label now allows for telehealth, mifepristone has emerged as an option for patients who are either unable to travel to clinic or for other reasons wish to have an abortion in the privacy of their own home. As part of efforts to limit abortion access, some states have taken action to block the use of telehealth for abortion. Among the states that have not banned abortion, 13 states have at least one restriction that requires at least one trip to the clinic, and effectively ban telehealth for medication abortion.
Post-Dobbs v. Jackson Women’s Health Organization (2022). According to the Guttmacher Institute website (and as of June 11, 2025), since the Supreme Court overturned Roe v. Wade, 13 states are enforcing a near-total ban on abortion with very limited exceptions (Alabama, Arkansas, Idaho, Indiana, Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, South Dakota, Tennessee, Texas, and West Virginia). In other states, less restrictive rules are in place and include: abortion being banned after six weeks (Florida, Georgia, Iowa, and South Carolina); a 12-week ban (Nebraska and North Carolina); and, an 18-23 week ban (Kansas, Ohio, Utah, and Wisconsin). In Arizona, Florida, Oklahoma, and Texas mailing abortion pills is also banned. In Louisiana, medication abortion can only be provided after in-person visit because state requires pills to be dispensed in person.
According to a February 16, 2023 story in the New York Times, one commonality among many of the bans is that enforcement is enhanced through the targeting of medical providers. For example, in Texas it is a felony to perform an abortion, unless it is needed to save the life of the patient, and provides for civil liability and licensure revocation. The Texas law also provides that any person, other than an officer or employee of a state or local governmental entity in Texas, and regardless if they suffered any actual harm, may bring a civil action to enforce its provisions, which includes liability of $10,000 plus costs and fees if a plaintiff prevails while a defendant is prohibited from recovering their own costs and fees if they prevail. Idaho enacted a similar law, which provides for liability of $20,000 plus costs and fees if a plaintiff prevails. Oklahoma also enacted a similar law to Texas’ and enacted criminal penalties for the performance of an abortion, except when performed to save the life of a pregnant person, with punishment of up to ten years in prison or fines of up to $100,000.
In January 2025, a New York physician was indicted in Louisiana for providing medication abortion across state lines. According to a March 19, 2025 NPR report, Dr. Margaret Carpenter was charged alongside a Louisiana mother who allegedly received the mailed package and gave the pills prescribed by Carpenter to her minor daughter. The teen wanted to keep the pregnancy and called 911 after taking the pills, according to an NPR interview with the Louisiana district attorney prosecuting the case. The charges carry a possible five-year prison sentence. On February 11, Louisiana's governor signed an extradition warrant for Carpenter. He later posted a video arguing she "must face extradition to Louisiana, where she can stand trial and justice will be served." New York's governor countered by releasing her own video, confirming she was refusing to extradite Carpenter. According to a March 27, 2025 AP story, in a separate case involving Dr. Carpenter, a Texas judge ordered her to pay a penalty for allegedly breaking that state's law by prescribing abortion medication via telemedicine. The Texas attorney general's office followed up by asking a New York court to enforce the default civil judgment, which is $113,000 with attorney and filing fees. The acting Ulster County clerk refused, stating, “In accordance with the New York State Shield Law, I have refused this filing and will refuse any similar filings that may come to our office.” According to the March 2025 NPR report, eight states (New York, Maine, California, Colorado, Massachusetts, Rhode Island, Vermont, and Washington) have passed laws since 2022 to protect doctors who mail abortion pills out of state, and thereby block them from extradition in such cases. But the Louisiana case is the first criminal test of these relatively new "shield laws."
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
Senate Rule 28.8
SUPPORT: (Verified 8/18/25)
All Above All (co-source)
Attorney General Rob Bonta (co- source)
Black Women for Wellness Action Project (co- source)
California Commission on Status of Women and Girls (co- source)
California Latinas for Reproductive Justice (co- source)
Essential Health Access (co- source)
National Health Law Program (co- source)
Planned Parenthood Affiliates of California (co- source)
Reproductive Freedom for All California (co- source)
American College of Obstetricians & Gynecologists- District IX
California Civil Liberties Advocacy
California Medical Association
California Nurse Midwives Association
California Primary Care Association Advocates
California Teachers Association
California Women Lawyers
Citizens for Choice
County of Los Angeles
Equality California
NextGen California
Osteopathic Medical Board of California
San Francisco Bay Area Black & Jewish Coalition
Women’s Health Specialists
Women’s Liberation Front
One individual
OPPOSITION: (Verified 8/18/25)
California Family Council
Lighthouse Baptist Church
Pacific Justice Institute – Center for Public Policy
One individual
ARGUMENTS IN SUPPORT: The sponsors of this bill write that with over 20 years of available data, medication abortion has proven to be remarkably safe and effective. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. This bill will preserve the constitutional and statutory right to choose and obtain abortions in the state of California by ensuring there is sufficient access to medication abortion and the ability to facilitate access. Additionally, this bill shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering medication abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance. Sponsors further state that providers and researchers estimate that over 60% of all abortions in the U.S. are done using medication abortion. With over twenty years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4% risk of major complications, and a mortality rate of only .00064%. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a .0049% mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the U.S. has an overall maternal mortality rate of .0329%. Medication abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities.
ARGUMENTS IN OPPOSITION: California Family Council writes that this bill is working off of the pretense that Mifepristone is “safe and effective”, yet the Ethics and Public Policy Center (EPPC) reports that 11% of women experience Serious Adverse Events within 45 days, 22 times higher than the drug label’s claim. This includes 3,062 ectopic pregnancies, 11,707 infections, 24,563 repeated surgical abortions, and 28,658 hemorrhages, alongside 1,445 FDA-reported adverse events. Reducing oversight in the face of such data is reckless, not compassionate. Pacific Justice Institute – Center for Public Policy states that this bill’s expansion of legal protections for mailing and distributing abortion drugs would likely increase their use through channels like telehealth and pharmacies, further reducing critical medical oversight. The FDA has already weakened safety protocols by eliminating requirements for in-person physician visits, mandatory adverse event reporting, and limiting prescriptions to physicians. These changes have coincided with higher complication rates, as the EPPC study confirms. By facilitating broader distribution, this bill risks exacerbating these harms, leaving women vulnerable to severe complications like hemorrhaging or incomplete abortions, which often require urgent surgical intervention.
ASSEMBLY FLOOR: 61-10, 5/12/25
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Garcia, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NOES: Castillo, DeMaio, Ellis, Gallagher, Hadwick, Lackey, Macedo, Patterson, Sanchez, Ta
NO VOTE RECORDED: Chen, Davies, Dixon, Flora, Jeff Gonzalez, Hoover, Stefani, Tangipa
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
8/20/25 23:06:51
**** END ****
Senator Thomas Umberg, Chair
2025-2026 Regular Session
Bill No: AB 54 (Author:Krell)
Version: July 1, 2025
Hearing Date: July 15, 2025
Fiscal: Yes
Urgency: No
AMConsultant:
SUBJECT
Access to Safe Abortion Care Act
DIGEST
The bill establishes the Access to Safe Abortion Care Act, under which the Legislature reaffirms that it has been, and continues to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in this state. The bill prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance.
EXECUTIVE SUMMARY
In 2022, the U.S. Supreme Court published its opinion in Dobbs v. Jackson Women’s Health ((2022) 597 U.S. 215.), overturning 50 years of precedent and revoking a constitutional right. Prior to Dobbs, the Supreme Court had continuously upheld the holding of Roe v. Wade, that found the implied constitutional right to privacy extended to a person’s decision whether to terminate a pregnancy, while allowing some state regulation of abortion access as permissible. ((1973) 410 U.S. 113.) Under the Dobbs decision, the Supreme Court held that states should be allowed to decide how to regulate abortion and that a strong presumption of validity should be afforded to those state laws. (Dobbs, at 301.) As a result of the Dobbs decision, people in roughly half the country may lose access to abortion services or have them severely restricted. This bill seeks to address recent actions to restrict access to medication abortion, such as mifepristone, by reaffirming the legality of medication abortion in this state. The bill is sponsored by Attorney General Rob Bonta and supported by a large coalition of advocates for reproductive health care. The bill is opposed by several organizations that advocate against the right to reproductive health care. This bill passed the Senate Health Committee on a vote of 9 to 1.
PROPOSED CHANGES TO THE LAW
Existing law:
- Prohibits the state from denying or interfering with an individual’s reproductive freedom in their most intimate decisions, which includes their fundamental right to choose to have an abortion and their fundamental right to choose or refuse contraceptives. Specifies that this provision is intended to further the constitutional right to privacy guaranteed by Section 1 of Article I of the California Constitution, and the constitutional right to not be denied equal protection guaranteed by Section 7 of Article I of the California Constitution, and that nothing herein narrows or limits the right to privacy or equal protection. (Cal. Const., art. I, § 1.1.)
- Provides that all people are by nature free and independent and have inalienable rights including, among others, the right to privacy. (Cal. Const., art. I, § 1.)
- Establishes the Reproductive Privacy Act and provides that the Legislature finds and declares that every individual possesses a fundamental right of privacy with respect to personal reproductive decisions and, therefore, it is the public policy of the State of California that:
- every individual has the fundamental right to choose or refuse birth control;
- every individual has the fundamental right to choose to bear a child or to choose to obtain an abortion, with specified limited exceptions; and
- the state shall not deny or interfere with a person’s fundamental right to choose to bear a child or to choose to obtain an abortion, except as specifically permitted (Health & Saf. Code § 123460 et seq., § 123462.)
- Prohibits the state from denying or interfering with a pregnant person’s right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the woman or pregnant person. (Health and Saf. Code § 123466(a).)
- Provides that a law of another state that authorizes a person to bring a civil action against a person or entity who does any of the following is contrary to the public policy of this state:
- receives or seeks an abortion;
- performs or induces an abortion;
- knowingly engages in conduct that aids or abets the performance or inducement of an abortion; or
- attempts or intends to engage in the conduct described in a) through c). (Health & Safe. Code § 123467.5(a).)
- Prohibits licensing boards from disciplining healthcare providers based on out-of-state judgments related to sensitive services, including reproductive or gender-affirming healthcare. (Bus. & Prof. Code § 852.)
- Blocks the enforcement of certain out-of-state laws against individuals or providers offering such sensitive services. (Civ. Code §§ 1798.300 et seq.)
This bill:
- Provides that, consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and continues to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
- Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance with this chapter.
- This provision is to be applied retroactively to January 1, 2020.
- Provides that these provisions are severable. If any provision or its application is held invalid, that invalidity is not to affect other provisions or applications that can be given effect without the invalid provision or application.
- Makes the following Legislative findings and declarations:
- In 1973, the United States Supreme Court recognized a federal constitutional right to an abortion in Roe v. Wade (1973) 410 U.S. 113. For nearly 50 years, and through numerous challenges, the federal courts consistently upheld this fundamental right. However, in 2022, the United States Supreme Court reversed course. In Dobbs v. Jackson Women’s Health Organization (2022) 597 U.S. 215, the Court threw out decades of precedent, overruled Roe, and concluded that there was no federal constitutional right to an abortion. In reaching that conclusion, the Court “return[ed]” the authority to regulate abortion to the “people and their elected representatives” (id. at 302).
- Both before and after the Dobbs decision was announced, California enacted numerous measures to protect the right to an abortion at the state level. Chief among these is Section 1.1 of Article I of the California Constitution, which states that individuals in California have a constitutional right to choose to have an abortion.
- California’s decision to protect access to abortion as a matter of both individual rights and sound public policy is consistent with the promise of the Dobbs decision that abortion would be entrusted to the states and the normal political processes. However, in the wake of Dobbs, there are numerous threats to access to abortion care and reproductive rights, even in California. In particular, an ongoing court case, Missouri et al. v. U.S. FDA et al., Case No. 2:22-cv-00223-Z (N.D. Tex), threatens to upend access to mifepristone.
- In 2000, the United States Food and Drug Administration (FDA) approved mifepristone for use in the termination of pregnancy. In April 2019, the FDA approved a generic version of mifepristone.
- Mifepristone is usually used in combination with misoprostol to terminate a pregnancy. Misoprostol can also be used on its own to terminate a pregnancy. When mifepristone and misoprostol are used in combination, or when misoprostol is used alone to terminate a pregnancy, this is referred to as a “medication abortion,” to distinguish it from a procedural abortion.
- Today, providers and researchers estimate that over 60 percent of all abortions in the United States are done using medication abortion.
- With over 20 years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4-percent risk of major complications, and a mortality rate of only 0.00064 percent. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a 0.0049-percent mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the United States has an overall maternal mortality rate of 0.0329 percent.
- Instrumentalities of the State of California regularly acquire and provide mifepristone and misoprostol. The five medical centers owned and operated by the University of California, for instance, all routinely acquire and use mifepristone and misoprostol for their patients in a variety of contexts.
- Pursuant to the College Student Right to Access Act, each public university student health center (including at the University of California and California State University systems) is required to offer abortion by medication techniques onsite.
- The widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the State of California, including safeguarding the health and welfare of Californians — as a safe, effective, and accessible means of terminating a pregnancy, and by providing medical providers with safe and effective options to treat their patients under a wide variety of circumstances.
COMMENTS
- Stated need for the bill
The author writes:
In 2022 California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. As former Chief Legal Counsel to Planned Parenthood, I fought federal efforts to eliminate access to reproductive care in the first Trump Administration. It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. AB 54 shields manufacturers, distributers, and health care provides from liability for providing medication abortion to Californians.
Attorney General Rob Bonta, the sponsor of the bill, writes:
[…] At a time when access to abortion care is under attack across this nation, Attorney General Bonta remains committed to ensuring that reproductive health care is a fundamental right protected and secured for all Californians. A vital part of abortion care is access to Medication Abortion. […]
There are emerging threats to the availability of Medication Abortion, and we must do everything we can to ensure Californians continue to have access to this critical medication.
AB 54 will continue to safeguard the constitutional and statutory right to choose and obtain abortions in California by ensuring there is sufficient access to Medication Abortion. Additionally, AB 54 shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering Medication Abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance.
- Reproductive health care
In 2022, the U.S. Supreme Court published its opinion in Dobbs v. Jackson Women’s Health (2022) 597 U.S. 215.), overturning 50 years of precedent and revoking, for the first time, a constitutional right. Prior to Dobbs, the Supreme Court had continuously upheld the holding of Roe v. Wade, that found the implied constitutional right to privacy extended to a person’s decision whether to terminate a pregnancy, while allowing some state regulation of abortion access as permissible. ((1973) 410 U.S. 113.) In the wake of Dobbs, numerous states now have laws prohibiting or severely limiting abortion and have enacted laws attempting to punish those who seek safe and reliable reproductive healthcare in states where it is still legal to seek abortion care. According to the Guttmacher Institute, 16 states have effectively banned abortion and another 10 have become very restrictive or restrictive.[1]
- California is a Reproductive Freedom State
The California Supreme Court held in 1969 that the state constitution’s implied right to privacy extends to an individual’s decision about whether or not to have an abortion. (People v. Belous (1969) 71 Cal.2d 954.) This was the first time an individual’s right to abortion was upheld in a court. In 1972 the California voters passed a constitutional amendment that explicitly provided for the right to privacy in the state constitution. (Prop. 11, Nov. 7, 1972 gen. elec.) California statutory law provides, under the Reproductive Privacy Act, that the Legislature finds and declares every individual possesses a fundamental right of privacy with respect to personal reproductive decisions, which entails the right to make and effectuate decisions about all matters relating to pregnancy; therefore, it is the public policy of the State of California that every individual has the fundamental right to choose or refuse birth control, and every individual has the fundamental right to choose to bear a child or to choose to obtain an abortion. (Health & Saf. Code § 123462.) In 2019, Governor Newsom issued a proclamation reaffirming California’s commitment to making reproductive freedom a fundamental right in response to the numerous attacks on reproductive rights across the nation.[2] In September 2021, more than 40 organizations came together to form the California Future Abortion Council (CA FAB) to identify barriers to accessing abortion services and to recommend policy proposals to support equitable and affordable access for not only Californians but all who seek care in the state.
In response to the Dobbs decision, California enacted a comprehensive package of legislation expanding, protecting, and strengthening access to reproductive health care, including abortions, for all Californians and people seeking such care in our state.[3] One such law, SB 345 (Skinner, Ch. 260, Stats. 2023) provided safeguards for professional licenses of California healthcare providers from of out-of-state statutes attempting to punish these professionals for providing care legal in the state. Additionally, the voters overwhelmingly approved Proposition 1 (Nov. 8, 2022 gen. elec.), and enacted an express constitutional right in the state constitution that prohibits the state from interfering with an individual’s reproductive freedom in their most intimate decisions.
- Out-of-state statutes denying or chilling access to reproductive health care
Many states have enacted statutes targeting providers of abortions or those who “aid and bet” a person in receiving an abortion. For example, a Texas law prohibits a physician from knowingly performing or inducing an abortion on a pregnant woman if the physician detected a fetal heartbeat for the unborn child, as specified, or failed to perform a test to detect a fetal heartbeat.[4] (Tex. Health & Safety Code § 171.201 et seq. (enacted through Texas Senate Bill 8).) This law essentially places a near-categorical ban on abortions beginning six weeks after a person’s last menstrual period, which is before many people even realize they are pregnant and occurs months before fetal viability.[5] The Texas law has far reaching implications, not solely for the person receiving an abortion or performing abortion services. This is evidenced in the provisions that prohibit anyone from “aiding and abetting” a person in obtaining an abortion, which could implicate and impose significant civil liability upon a person providing transportation to or from an abortion clinic, a person donating to a fund to assist individuals receiving an abortion, or even a person who simply discusses getting an abortion with someone. (Tex. Health & Safety Code § 171.208.) The Texas law provides that any person, other than an officer or employee of a state or local governmental entity in Texas, may bring a civil action to enforce its provisions, which includes liability of $10,000 plus costs and fees if a plaintiff prevails while a defendant is prohibited from recovering their own costs and fees if they prevail. (Id. at § 171.201(b) & (i).) Other states have already followed suit.
Additionally, many abortion bans target providers of abortions through criminal and administrative penalties, in addition to civil liability. For example, in Texas it is a felony to perform an abortion, unless it is needed to save the life of the patient, and provides for civil liability and licensure revocation. (Tex. Health & Safety Code § 171.201 et. seq.) In six states with abortion bans—Arkansas, Georgia, Idaho, Missouri, North Dakota, and Tennessee—prosecutors can criminally prosecute health care professionals for performing abortions and providers are only allowed to offer evidence that the procedure was necessary to save the patient until after they are charged.[6] These laws put providers in extremely difficult positions where they have to make legal and ethical judgments about treating a patient whose health or life may be in jeopardy while facing the very real potential of being held criminally or civilly liable or having their medical license threatened.
- Targeting of medication abortion
The FDA has approved the use of mifepristone for abortion in a two-drug regimen with misoprostol since 2000. Medication abortion does not require a clinical setting and has been demonstrated over decades of research and studies to be safe and effective.[7] According to the Senate Health Committee analysis of this bill:
The FDA has found that medication abortion is a safe and highly effective method of pregnancy termination. Medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and a mortality rate of 0.00064%. Telehealth can be used to expand access to abortion services in areas where the number of clinicians who provide that care is limited. Many patients, particularly those who live in rural communities, must travel long distances to obtain abortion services even in states where abortion is still permitted. Because the updated FDA label now allows for telehealth, mifepristone has emerged as an option for patients who are either unable to travel to clinic or for other reasons wish to have an abortion in the privacy of their own home. As part of efforts to limit abortion access, some states have taken action to block the use of telehealth for abortion. Among the states that have not banned abortion, 13 states have at least one restriction that requires at least one trip to the clinic, and effectively ban telehealth for medication abortion.[8]
Just recently, the FDA Commissioner, Marty Makary, committed to reviewing the abortion drug mifepristone in response to a letter from Senator Josh Hawley of Missouri, which claims that data from the Ethics and Public Policy Center on mifepristone raises concerns about the medication’s safety.[9] However, “the study is deeply flawed and filled with what researchers have called ‘junk science.’”[10] Additionally, Health and Human Services Secretary Robert F. Kennedy Jr. has also asked for a review of mifepristone based on the same study.[11] Furthermore, the ongoing case of Missouri et al. v. U.S. FDA et al., Case No. 2:22-cv-00223-Z (N.D. Tex) also threatens access to abortion medication. Under the Missouri case, plaintiffs are alleging that the FDA approval of the abortion drug mifepristone and FDA’s regulations increasing safe access to mifepristone violate various federal laws.
In May of this year, a bill passed the Texas Senate that allows Texans to sue out-of-state prescribers and distributors of abortion medication and those who help pregnant persons gain access to those drugs. (Texas Senate Bill 2880.) The bill has a civil enforcement mechanism that is similar to the one in Texas Senate Bill 8. In 2021, Texas passed Senate Bill 4, which requires in-person examinations in order to be prescribed any abortion medication and prohibits the delivery of abortion medication by mail. A violation of these provisions subjects a person to felony charges.
- This bill enacts the Access to Safe Abortion Care Act
This bill seeks to affirm that it is and will continue to be lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in this state. The bill also provides that a manufacturer, distributor, authorized health care provider, pharmacist, or individual will not be subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering brand name or generic mifepristone or any drug used for medication abortion on or after January 1, 2020, that is lawful in California. The bill provides that its provisions are severable and that if any provision of this bill or its application is held invalid, that invalidity will not affect other provisions or applications that can be given effect without the invalid provision or application. The bill is consistent with the California’s public policy of being a reproductive freedom state and reinforces existing protections around medication abortion.
SUPPORT
Attorney General, Rob Bonta (sponsor)
All Above All
American College of Obstetricians & Gynecologists - District IX
California Commission on the Status of Women and Girls
California Civil Liberties Advocacy
California Medical Association
California Nurse Midwives Association
California Teachers Association
California Women Lawyers
California Women's Law Center
County of Los Angeles Board of Supervisors
CPCA Advocates, Subsidiary of the California Primary Care Association
Equality California
Essential Access Health
NextGen California
Osteopathic Medical Board of California
Planned Parenthood Affiliates of California
Reproductive Freedom for All California
San Francisco Bay Area Black & Jewish Unity Coalition
Women's Health Specialists
OPPOSITION
California Baptists for Biblical Values
California Family Council
Lighthouse Baptist Church
Pacific Justice Institute – Center for Public Policy
RELATED LEGISLATION
Pending Legislation: AB 260 (Aguiar-Curry, 2025), among other things, prohibits subjecting a healing arts practitioner who is authorized to prescribe, furnish, order, or administer dangerous drugs to civil, criminal, disciplinary, or other administrative actions for prescribing, furnishing, ordering, or administering mifepristone or other medication abortion drugs for a use that is different from the use for which that drug has been approved for marketing by the FDA or that varies from an approved risk evaluation and mitigation strategy under federal law, as specified. AB 260 is currently pending in the Senate Appropriations Committee.
Prior Legislation:
SCA 10 (Atkins, Ch. 97, Stats. 2022) amended the California Constitution to prohibit the state from denying or interfering with an individual’s reproductive freedom in their most intimate decisions, which includes their fundamental right to choose to have an abortion and their fundamental right to choose or refuse contraceptives. SCA 10 was placed on the 2022 November general election ballot as Proposition 1, and was approved by the voters.
AB 1666 (Bauer-Kahan, Ch. 42, Stats. 2022) prohibited the enforcement in this state of out-of-state laws authorizing a civil action against a person or entity that receives or seeks, performs or induces, or aids or abets the performance of an abortion, or who attempts or intends to engage in those actions and declares those out-of-state laws to be contrary to the public policy of this state.
AB 2091 (Mia Bonta, Ch. 628, Stats. 2022), among other things, prohibited compelling a person to identify or provide information that would identify an individual who has sought or obtained an abortion in a state, county, city, or other local criminal, administrative, legislative, or other proceeding if the information is being requested based on another state’s laws that interfere with a person’s right to choose or obtain an abortion or a foreign penal civil action.
AB 2223 (Wicks, Ch. 629, Stats. 2022), among other things, authorized a party aggrieved by a violation of the Reproductive Privacy Act to bring a civil action against an offending state actor, as specified, and provides that every individual possesses a fundamental right of privacy with respect to personal reproductive decisions, which entails the right to make and effectuate decisions about all matters relating to pregnancy, including prenatal care, childbirth, postpartum care, contraception, sterilization, abortion care, miscarriage management, and infertility care.
PRIOR VOTES
Senate Health Committee (Ayes 9, Noes 1)
Assembly Floor (Ayes 61, Noes 10)
Assembly Appropriations Committee (Ayes 11, Noes 1)
Assembly Judiciary Committee (Ayes 8, Noes 1)
Assembly Health Committee (Ayes 12, Noes 0)
**************
Interactive Map: US Abortion Policies and Access After Roe, Guttmacher Institute, (as of Jun. 5, 2025), available at https://states.guttmacher.org/policies. ↑
California Proclamation on Reproductive Freedom (May 31, 2019) available at https://www.gov.ca.gov/wp-content/uploads/2019/05/Proclamation-on-Reproductive-Freedom.pdf. ↑
Kristen Hwang, Newsom signs abortion protections into law, CalMatters (Sept. 27, 2022), available at https://calmatters.org/health/2022/09/california-abortion-bills/. ↑
Committee staff notes that the application of the term “fetal heartbeat” as applied in restrictive abortion laws, such as ones in Texas, may be misleading. See Kaitlin Sullivan, Heartbeat bills: Is there a fetal heartbeat at six weeks of pregnancy?, NBC News, (Apr. 17, 2022) https://www.nbcnews.com/health/womens-health/heartbeat-bills-called-fetal-heartbeat-six-weeks-pregnancy-rcna24435. ↑
See Whole Woman's Health v. Jackson (2021) 141 S. Ct. 2494, at 24998 (dis. opn. Sotomayor, Breyer, & Kagan). ↑
Christine Vestal, Some Abortion Bans Put Patients, Doctors at Risk in Emergencies, Pew Trusts (Sept. 1, 2022), available at https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2022/09/01/some-abortion-bans-put-patients-doctors-at-risk-in-emergencies. ↑
Medication abortion, Guttmacher Institute, (as of Apr. 23, 2025), available at https://www.guttmacher.org/state-policy/explore/medication-abortion. ↑
Sen. Health Comm. analysis SB 54 (2025-26 reg. sess.) as amended Mar. 17, 2025 at p. 3. ↑
Alejandra O’Connell-Domenech, FDA commissioner pledges to investigate mifepristone, The Hill, (June 3, 2025.), available at https://thehill.com/policy/healthcare/5330774-marty-makary-fda-mifepristone-review/. ↑
Ibid. ↑
Alejandra O’Connell-Domenech, Reproductive-rights groups push against Kennedy’s mifepristone review, The Hill, (May 19, 2025), available at https://thehill.com/policy/healthcare/5304436-fda-mifepristone-review-abortion-rights-advocates/. ↑
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: AB 54
AUTHOR: | Krell, Aguiar-Curry | ||
VERSION: | March 17, 2025 | ||
HEARING DATE: | June 25, 2025 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Access to Safe Abortion Care Act
SUMMARY:
Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020.
Existing law:
- Establishes the Reproductive Privacy Act (RPA), which prohibits the state from denying or interfering with a woman’s right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the woman. [HSC §123460, et seq.]
- Prohibits a person who aids or assists a pregnant person in exercising their rights under RPA from being subject to civil or criminal liability or penalty, or otherwise being deprived of their rights, based solely on their actions to aid or assist a pregnant person in exercising their rights under RPA with the pregnant person's voluntary consent. [HSC §123467]
- Provides that a law of another state that authorizes a person to bring a civil action against a person or entity who does any of the following is contrary to the public policy of this state: receives or seeks an abortion; performs or induces an abortion; knowingly engages in conduct that aids or abets the performance or inducement of an abortion; or, attempts or intends to engage in the aforementioned conduct. [HSC §123467.5]
This bill:
- Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020, in accordance with state laws, applicable and accepted standards of care, and good faith compliance with this bill. Requires this bill to be applied retroactively to January 1, 2020.
- States that, consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
- Makes this bill’s provisions severable: if any provision or its application is held invalid, that invalidity is prohibited from affecting other provisions or applications that can be given effect without the invalid provision or application.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, there are no state costs associated with this bill.
PRIOR VOTES:
Assembly Floor: | 61 - 10 |
Assembly Appropriations Committee: Assembly Judiciary Committee | 11 - 1 8 - 1 |
Assembly Health Committee: | 12 - 0 |
COMMENTS:
- Author’s statement. According to the author, in 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. As former Chief Legal Counsel to Planned Parenthood, I fought federal efforts to eliminate access to reproductive care in the first Trump Administration. It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. This bill shields manufacturers, distributers, and health care providers from liability for providing medication abortion to Californians.
- Abortion. According to the Center for Diseases Control and Prevention (CDC), a legal induced abortion is defined as an intervention performed by a licensed clinician that is intended to terminate an ongoing pregnancy. Ending a pregnancy with medications is an option for women who are less than ten weeks pregnant and would like to have an abortion at home with a less invasive procedure. The CDC reports that 613,383 abortions were reported nationally from 48 reporting areas in 2022. From 2021 to 2022, the total number of abortions decreased 2%, and the number decreased 5% between 2013 and 2022. In 2022, women in their 20s accounted for more than half of abortions (56.5%). By contrast, adolescents under 15 years (0.2%) and women over 40 (3.6%) years accounted for the lowest percentages of abortions. In 2022, nearly all abortions (92.8%) were performed at or less than 13 weeks gestation. That year, the highest proportion of abortions were performed by early medication abortion at or less than nine weeks’ gestation (53.3%), followed by surgical abortion at or less than 13 weeks gestation (35.5%), surgical abortion at more than 13 weeks gestation (6.9%), and medication abortion at more than nine weeks gestation (4.3%). In 2021, the most recent year for which data was reviewed for pregnancy-related deaths, five women died as a result of complications from legal induced abortion.
- California data. According to the Guttmacher Institute, 182,170 abortions were provided by clinicians in California in 2024, though not all those abortions were provided to state residents. In January 2025, there were an estimated 17,020 clinician-provided abortions, and that number was consistent with the previous six-month period (average of 15,000 abortions per month). Data for 2023, the first full year after the U.S. Supreme Court overturned Roe v. Wade, show that an estimated total of 179,120 clinician-provided abortions took place in California (an increase of 1.7%).
- Medication abortion. According to a March 2024 Kaiser Family Foundation factsheet, medication abortion is a pregnancy termination protocol that involves taking two different drugs approved for use up to the first 10 weeks of pregnancy by the U.S. Food and Drug Administration (FDA). The World Health Organization has authorized use up to 12 weeks of pregnancy. Since the FDA first approved the drug in 2000, its use in the U.S. has grown. In 2023, 63% of abortions in the U.S. were medication abortions. The most common medication abortion regimen involves the use of two different medications: mifepristone and misoprostol. Mifepristone, also known as the abortion pill or RU-486, is sold under the brand name Mifeprex and through a generic manufactured by GenBioPro. Mifepristone works by blocking progesterone, a hormone essential to the development of a pregnancy, and prevents an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. A follow-up visit can be scheduled a week or two later to confirm that the pregnancy was terminated via ultrasound or blood test. The FDA has found that medication abortion is a safe and highly effective method of pregnancy termination. Medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and a mortality rate of 0.00064%. Telehealth can be used to expand access to abortion services in areas where the number of clinicians who provide that care is limited. Many patients, particularly those who live in rural communities, must travel long distances to obtain abortion services even in states where abortion is still permitted. Because the updated FDA label now allows for telehealth, mifepristone has emerged as an option for patients who are either unable to travel to clinic or for other reasons wish to have an abortion in the privacy of their own home. As part of efforts to limit abortion access, some states have taken action to block the use of telehealth for abortion. Among the states that have not banned abortion, 13 states have at least one restriction that requires at least one trip to the clinic, and effectively ban telehealth for medication abortion.
- Post-Dobbs v. Jackson Women’s Health Organization (2022). According to the Guttmacher Institute website (and as of June 11, 2025), since the Supreme Court overturned Roe v. Wade, 13 states are enforcing a near-total ban on abortion with very limited exceptions (Alabama, Arkansas, Idaho, Indiana, Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, South Dakota, Tennessee, Texas, and West Virginia). In other states, less restrictive rules are in place and include: abortion being banned after six weeks (Florida, Georgia, Iowa, and South Carolina); a 12-week ban (Nebraska and North Carolina); and, an 18-23 week ban (Kansas, Ohio, Utah, and Wisconsin). In Arizona, Florida, Oklahoma, and Texas mailing abortion pills is also banned. In Louisiana, medication abortion can only be provided after in-person visit because state requires pills to be dispensed in person.
According to a February 16, 2023 story in the New York Times, one commonality among many of the bans is that enforcement is enhanced through the targeting of medical providers. For example, in Texas it is a felony to perform an abortion, unless it is needed to save the life of the patient, and provides for civil liability and licensure revocation. The Texas law also provides that any person, other than an officer or employee of a state or local governmental entity in Texas, and regardless if they suffered any actual harm, may bring a civil action to enforce its provisions, which includes liability of $10,000 plus costs and fees if a plaintiff prevails while a defendant is prohibited from recovering their own costs and fees if they prevail. Idaho enacted a similar law, which provides for liability of $20,000 plus costs and fees if a plaintiff prevails. Oklahoma also enacted a similar law to Texas’ and enacted criminal penalties for the performance of an abortion, except when performed to save the life of a pregnant person, with punishment of up to ten years in prison or fines of up to $100,000.
In January 2025, a New York physician was indicted in Louisiana for providing medication abortion across state lines. According to a March 19, 2025 NPR report, Dr. Margaret Carpenter was charged alongside a Louisiana mother who allegedly received the mailed package and gave the pills prescribed by Carpenter to her minor daughter. The teen wanted to keep the pregnancy and called 911 after taking the pills, according to an NPR interview with the Louisiana district attorney prosecuting the case. The charges carry a possible five-year prison sentence. On February 11, Louisiana's governor signed an extradition warrant for Carpenter. He later posted a video arguing she "must face extradition to Louisiana, where she can stand trial and justice will be served." New York's governor countered by releasing her own video, confirming she was refusing to extradite Carpenter. According to a March 27, 2025 AP story, in a separate case involving Dr. Carpenter, a Texas judge ordered her to pay a penalty for allegedly breaking that state's law by prescribing abortion medication via telemedicine. The Texas attorney general's office followed up by asking a New York court to enforce the default civil judgment, which is $113,000 with attorney and filing fees. The acting Ulster County clerk refused, stating, “In accordance with the New York State Shield Law, I have refused this filing and will refuse any similar filings that may come to our office.” According to the March 2025 NPR report, eight states (New York, Maine, California, Colorado, Massachusetts, Rhode Island, Vermont, and Washington) have passed laws since 2022 to protect doctors who mail abortion pills out of state, and thereby block them from extradition in such cases. But the Louisiana case is the first criminal test of these relatively new "shield laws."
- Double referral. This bill has been double referred. Should it pass out of this Committee, it will be referred to the Senate Judiciary Committee.
- Related legislation. AB 40 (Bonta) adds “reproductive health services, including abortion” to the definition of "emergency services and care" in existing law for purposes of provisions requiring hospitals and physicians to provide emergency care to patients without regard to ability to pay. AB 40 passed this Committee by a vote of 7-1 on June 11, 2025.
AB 260 (Aguiar-Curry), among other provisions: a) permits CDPH to adopt regulations specific to medication abortion drugs, including exempting those drugs from certain requirements if the drugs are no longer approved by the FDA; b) prohibits CDPH from taking criminal, civil, professional discipline, or licensing action against a clinic or health facility for manufacturing, transporting, or engaging in certain acts relating to medication abortion drugs; c) prohibits a health plan contract or a group or individual health insurance policy that covers prescription drugs from limiting or excluding coverage for brand name or generic mifepristone, regardless of its FDA approval status; and, d) requires DHCS to update provider enrollment requirements and procedures for providers who offer reproductive health care services exclusively thorough telehealth. AB 260 passed this Committee by a vote of 6-1 on June 11, 2025.
- Prior legislation. SB 345 (Skinner, Chapter 260, Statutes of 2023) enacts various safeguards against the enforcement of other states’ laws that prohibit, criminalize, sanction, authorize civil liability against, or otherwise interfere with a person, provider, or other entity in California that offers reproductive health care services or gender-affirming health care services.
SB 487 (Atkins, Chapter 261, Statutes of 2023) prohibits health plans and health insurers from terminating, discriminating against, or otherwise penalizing a provider based on a civil judgment, criminal conviction, or another disciplinary action in another state if the judgment, conviction, or disciplinary action is solely based on the application of another state’s law that interferes with a person’s right to receive care that would be lawful if provided in California.
SB 487 permits the Department of Health Care Services to elect not to suspend a Medi-Cal provider who has a license, certificate, or other approval to provide health care suspended or revoked in another state if the revocation or suspension is based solely on conduct that is not deemed to be unprofessional conduct under California law.
AB 1666 (Bauer-Kahan, Chapter 42, Statutes of 2022) prohibits the enforcement of out-of-state laws authorizing a civil action against a person or entity that receives or performs or induces, or aids or abets the performance of an abortion, or who attempts or intends to engage in those actions and declares those out-of-state laws to be contrary to the public policy of this state.
AB 2091 (Mia Bonta, Chapter 628, Statutes of 2022), among other things, prohibits compelling a person to identify or provide information that would identify an individual who has sought or obtained an abortion in a state, county, city, or other local criminal, administrative, legislative, or other proceeding if the information is being requested based on another state’s laws that interfere with a person’s right to choose or obtain an abortion or a foreign penal civil action.
AB 2223 (Wicks, Chapter 629, Statutes of 2022) prohibits a person from being subject to civil or criminal liability, or otherwise deprived of their rights, based on their actions or omissions with respect to their pregnancy or actual, potential, or alleged pregnancy outcome or based solely on their actions to aid or assist a pregnant person who is exercising their reproductive rights.
SB 1301 (Kuehl, Chapter 385, Statutes of 2002) enacts the RPA, which provides that every individual possesses a fundamental right of privacy with respect to reproductive decisions, including the fundamental right to choose or refuse birth control, and the fundamental right to choose to bear a child or obtain an abortion.
- Support. The sponsors of this bill write that with over 20 years of available data, medication abortion has proven to be remarkably safe and effective. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. This bill will preserve the constitutional and statutory right to choose and obtain abortions in the state of California by ensuring there is sufficient access to medication abortion and the ability to facilitate access. Additionally, this bill shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering medication abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance. Sponsors further state that providers and researchers estimate that over 60% of all abortions in the U.S. are done using medication abortion. With over twenty years of available data, medication abortion has proven to be remarkably safe and effective. Medication abortion has only a 0.4% risk of major complications, and a mortality rate of only .00064%. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a .0049% mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the U.S. has an overall maternal mortality rate of .0329%. Medication abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities.
- Opposition. California Family Council writes that this bill is working off of the pretense that Mifepristone is “safe and effective”, yet the Ethics and Public Policy Center (EPPC) reports that 11% of women experience Serious Adverse Events within 45 days, 22 times higher than the drug label’s claim. This includes 3,062 ectopic pregnancies, 11,707 infections, 24,563 repeated surgical abortions, and 28,658 hemorrhages, alongside 1,445 FDA-reported adverse events. Reducing oversight in the face of such data is reckless, not compassionate. Pacific Justice Institute – Center for Public Policy states that this bill’s expansion of legal protections for mailing and distributing abortion drugs would likely increase their use through channels like telehealth and pharmacies, further reducing critical medical oversight. The FDA has already weakened safety protocols by eliminating requirements for in-person physician visits, mandatory adverse event reporting, and limiting prescriptions to physicians. These changes have coincided with higher complication rates, as the EPPC study confirms. By facilitating broader distribution, this bill risks exacerbating these harms, leaving women vulnerable to severe complications like hemorrhaging or incomplete abortions, which often require urgent surgical intervention.
- Technical amendment. In HSC 27051 (b): delete “mifepristone or misoprostol” and insert “brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state.”
SUPPORT AND OPPOSITION:
Support: All Above All (co-sponsor)
Attorney General Rob Bonta (co-sponsor)
Black Women for Wellness Action Project (co-sponsor)
California Commission on Status of Women and Girls (co-sponsor)
California Latinas for Reproductive Justice (co-sponsor)
Essential Health Access (co-sponsor)
National Health Law Program (co-sponsor)
Planned Parenthood Affiliates of California (co-sponsor)
Reproductive Freedom for All California (co-sponsor)
American College of Obstetricians & Gynecologists- District IX
California Civil Liberties Advocacy
California Medical Association
California Nurse Midwives Association
California Primary Care Association Advocates
California Teachers Association
Citizens for Choice
County of Los Angeles
Equality California
NextGen California
Osteopathic Medical Board of California
San Francisco Bay Area Black & Jewish Coalition
Women’s Health Specialists
One individual
Oppose: California Family Council
Pacific Justice Institute – Center for Public Policy
One individual
-- END --
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: AB 54
AUTHOR: | Krell, Aguiar-Curry | ||
VERSION: | March 17, 2025 | ||
HEARING DATE: | June 11, 2025 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Access to Safe Abortion Care Act
SUMMARY:
Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020.
Existing law:
- Establishes the Reproductive Privacy Act (RPA), which prohibits the state from denying or interfering with a woman’s right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the woman. [HSC §123460, et seq.]
- Prohibits a person who aids or assists a pregnant person in exercising their rights under RPA from being subject to civil or criminal liability or penalty, or otherwise being deprived of their rights, based solely on their actions to aid or assist a pregnant person in exercising their rights under RPA with the pregnant person's voluntary consent. [HSC §123467]
- Provides that a law of another state that authorizes a person to bring a civil action against a person or entity who does any of the following is contrary to the public policy of this state: receives or seeks an abortion; performs or induces an abortion; knowingly engages in conduct that aids or abets the performance or inducement of an abortion; or, attempts or intends to engage in the aforementioned conduct. [HSC §123467.5]
This bill:
- Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020, in accordance with state laws, applicable and accepted standards of care, and good faith compliance with this bill. Requires this bill to be applied retroactively to January 1, 2020.
- States that, consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
- Makes this bill’s provisions severable: if any provision or its application is held invalid, that invalidity is prohibited from affecting other provisions or applications that can be given effect without the invalid provision or application.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, there are no state costs associated with this bill.
PRIOR VOTES:
Assembly Floor: | 61 - 10 |
Assembly Appropriations Committee: Assembly Judiciary Committee | 11 - 1 8 - 1 |
Assembly Health Committee: | 12 - 0 |
COMMENTS:
- Author’s statement. According to the author, in 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. As former Chief Legal Counsel to Planned Parenthood, I fought federal efforts to eliminate access to reproductive care in the first Trump Administration. It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. This bill shields manufacturers, distributers, and health care providers from liability for providing medication abortion to Californians.
- Abortion. According to the Center for Diseases Control and Prevention (CDC), a legal induced abortion is defined as an intervention performed by a licensed clinician that is intended to terminate an ongoing pregnancy. Ending a pregnancy with medications is an option for women who are less than ten weeks pregnant and would like to have an abortion at home with a less invasive procedure. The CDC reports that 613,383 abortions were reported nationally from 48 reporting areas in 2022. From 2021 to 2022, the total number of abortions decreased 2%, and the number decreased 5% between 2013 and 2022. In 2022, women in their 20s accounted for more than half of abortions (56.5%). By contrast, adolescents under 15 years (0.2%) and women over 40 (3.6%) years accounted for the lowest percentages of abortions. In 2022, nearly all abortions (92.8%) were performed at or less than 13 weeks gestation. That year, the highest proportion of abortions were performed by early medication abortion at or less than nine weeks’ gestation (53.3%), followed by surgical abortion at or less than 13 weeks gestation (35.5%), surgical abortion at more than 13 weeks gestation (6.9%), and medication abortion at more than nine weeks gestation (4.3%). In 2021, the most recent year for which data was reviewed for pregnancy-related deaths, five women died as a result of complications from legal induced abortion.
- California data. According to the Guttmacher Institute, 182,170 abortions were provided by clinicians in California in 2024, though not all those abortions were provided to state residents. In January 2025, there were an estimated 17,020 clinician-provided abortions, and that number was consistent with the previous six-month period (average of 15,000 abortions per month). Data for 2023, the first full year after the U.S. Supreme Court overturned Roe v. Wade, show that an estimated total of 179,120 clinician-provided abortions took place in California (an increase of 1.7%).
- Medication abortion. According to a March 2024 Kaiser Family Foundation factsheet, medication abortion is a pregnancy termination protocol that involves taking two different drugs approved for use up to the first 10 weeks of pregnancy by the U.S. Food and Drug Administration (FDA). The World Health Organization has authorized use up to 12 weeks of pregnancy. Since the FDA first approved the drug in 2000, its use in the U.S. has grown. In 2023, 63% of abortions in the U.S. were medication abortions. The most common medication abortion regimen involves the use of two different medications: mifepristone and misoprostol. Mifepristone, also known as the abortion pill or RU-486, is sold under the brand name Mifeprex and through a generic manufactured by GenBioPro. Mifepristone works by blocking progesterone, a hormone essential to the development of a pregnancy, and prevents an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. A follow-up visit can be scheduled a week or two later to confirm that the pregnancy was terminated via ultrasound or blood test. The FDA has found that medication abortion is a safe and highly effective method of pregnancy termination. Medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and a mortality rate of 0.00064%. Telehealth can be used to expand access to abortion services in areas where the number of clinicians who provide that care is limited. Many patients, particularly those who live in rural communities, must travel long distances to obtain abortion services even in states where abortion is still permitted. Because the updated FDA label now allows for telehealth, mifepristone has emerged as an option for patients who are either unable to travel to clinic or for other reasons wish to have an abortion in the privacy of their own home. As part of efforts to limit abortion access, some states have taken action to block the use of telehealth for abortion. Among the states that have not banned abortion, 13 states have at least one restriction that requires at least one trip to the clinic, and effectively ban telehealth for medication abortion.
- Post-Dobbs v. Jackson Women’s Health Organization (2022). According to the Guttmacher Institute website (and as of May 28, 2025), since the Supreme Court overturned Roe v. Wade, 13 states are enforcing a near-total ban on abortion with very limited exceptions (Alabama, Arkansas, Idaho, Indiana, Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, South Dakota, Tennessee, Texas, and West Virginia). In other states, less restrictive rules are in place and include: abortion being banned after six weeks (Florida, Georgia, Iowa, and South Carolina); a 12-week ban (Nebraska and North Carolina); and, an 18-23 week ban (Kansas, Ohio, Utah, and Wisconsin). In Texas and Oklahoma, mailing abortion pills is also banned and criminal or civil liability to providers who mail abortion pills can be assigned. In Louisiana, medication abortion can only be dispensed in person.
According to a February 16, 2023 story in the New York Times, one commonality among many of the bans is that enforcement is enhanced through the targeting of medical providers. For example, in Texas it is a felony to perform an abortion, unless it is needed to save the life of the patient, and provides for civil liability and licensure revocation. The Texas law also provides that any person, other than an officer or employee of a state or local governmental entity in Texas, and regardless if they suffered any actual harm, may bring a civil action to enforce its provisions, which includes liability of $10,000 plus costs and fees if a plaintiff prevails while a defendant is prohibited from recovering their own costs and fees if they prevail. Idaho enacted a similar law, which provides for liability of $20,000 plus costs and fees if a plaintiff prevails. Oklahoma also enacted a similar law to Texas’ and enacted criminal penalties for the performance of an abortion, except when performed to save the life of a pregnant person, with punishment of up to ten years in prison or fines of up to $100,000.
In January 2025, a New York physician was indicted in Louisiana for providing medication abortion across state lines. According to a March 19, 2025 NPR report, Dr. Margaret Carpenter was charged alongside a Louisiana mother who allegedly received the mailed package and gave the pills prescribed by Carpenter to her minor daughter. The teen wanted to keep the pregnancy and called 911 after taking the pills, according to an NPR interview with the Louisiana district attorney prosecuting the case. The charges carry a possible five-year prison sentence. On February 11, Louisiana's governor signed an extradition warrant for Carpenter. He later posted a video arguing she "must face extradition to Louisiana, where she can stand trial and justice will be served." New York's governor countered by releasing her own video, confirming she was refusing to extradite Carpenter. According to a March 27, 2025 AP story, in a separate case involving Dr. Carpenter, a Texas judge ordered her to pay a penalty for allegedly breaking that state's law by prescribing abortion medication via telemedicine. The Texas attorney general's office followed up by asking a New York court to enforce the default civil judgment, which is $113,000 with attorney and filing fees. The acting Ulster County clerk refused, stating, “In accordance with the New York State Shield Law, I have refused this filing and will refuse any similar filings that may come to our office.” According to the March 2025 NPR report, eight states (New York, Maine, California, Colorado, Massachusetts, Rhode Island, Vermont, and Washington) have passed laws since 2022 to protect doctors who mail abortion pills out of state, and thereby block them from extradition in such cases. But the Louisiana case is the first criminal test of these relatively new "shield laws."
- Double referral. This bill has been double referred. Should it pass out of this Committee, it will be referred to the Senate Judiciary Committee.
- Related legislation. AB 40 (Bonta) adds “reproductive health services, including abortion” to the definition of "emergency services and care" in existing law for purposes of provisions requiring hospitals and physicians to provide emergency care to patients without regard to ability to pay. AB 40 is set to be heard in this Committee on June 11, 2025.
AB 260 (Aguiar-Curry), among other provisions: a) permits CDPH to adopt regulations specific to medication abortion drugs, including exempting those drugs from certain requirements if the drugs are no longer approved by the FDA; b) prohibits CDPH from taking criminal, civil, professional discipline, or licensing action against a clinic or health facility for manufacturing, transporting, or engaging in certain acts relating to medication abortion drugs; c) prohibits a health plan contract or a group or individual health insurance policy that covers prescription drugs from limiting or excluding coverage for brand name or generic mifepristone, regardless of its FDA approval status; and, d) requires DHCS to update provider enrollment requirements and procedures for providers who offer reproductive health care services exclusively thorough telehealth. AB 260 is set to be heard in this Committee on June 11, 2025.
- Prior legislation. SB 345 (Skinner, Chapter 260, Statutes of 2023) enacts various safeguards against the enforcement of other states’ laws that prohibit, criminalize, sanction, authorize civil liability against, or otherwise interfere with a person, provider, or other entity in California that offers reproductive health care services or gender-affirming health care services.
SB 487 (Atkins, Chapter 261, Statutes of 2023) prohibits health plans and health insurers from terminating, discriminating against, or otherwise penalizing a provider based on a civil judgment, criminal conviction, or another disciplinary action in another state if the judgment, conviction, or disciplinary action is solely based on the application of another state’s law that interferes with a person’s right to receive care that would be lawful if provided in California.
SB 487 permits the Department of Health Care Services to elect not to suspend a Medi-Cal provider who has a license, certificate, or other approval to provide health care suspended or revoked in another state if the revocation or suspension is based solely on conduct that is not deemed to be unprofessional conduct under California law.
AB 1666 (Bauer-Kahan, Chapter 42, Statutes of 2022) prohibits the enforcement of out-of-state laws authorizing a civil action against a person or entity that receives or performs or induces, or aids or abets the performance of an abortion, or who attempts or intends to engage in those actions and declares those out-of-state laws to be contrary to the public policy of this state.
AB 2091 (Mia Bonta, Chapter 628, Statutes of 2022), among other things, prohibits compelling a person to identify or provide information that would identify an individual who has sought or obtained an abortion in a state, county, city, or other local criminal, administrative, legislative, or other proceeding if the information is being requested based on another state’s laws that interfere with a person’s right to choose or obtain an abortion or a foreign penal civil action.
AB 2223 (Wicks, Chapter 629, Statutes of 2022) prohibits a person from being subject to civil or criminal liability, or otherwise deprived of their rights, based on their actions or omissions with respect to their pregnancy or actual, potential, or alleged pregnancy outcome or based solely on their actions to aid or assist a pregnant person who is exercising their reproductive rights.
SB 1301 (Kuehl, Chapter 385, Statutes of 2002) enacts the RPA, which provides that every individual possesses a fundamental right of privacy with respect to reproductive decisions, including the fundamental right to choose or refuse birth control, and the fundamental right to choose to bear a child or obtain an abortion.
- Support. The sponsors of this bill write that with over 20 years of available data, medication abortion has proven to be remarkably safe and effective. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. This bill will preserve the constitutional and statutory right to choose and obtain abortions in the state of California by ensuring there is sufficient access to medication abortion and the ability to facilitate access. Additionally, this bill shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering medication abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance. Sponsors further state that providers and researchers estimate that over 60% of all abortions in the U.S. are done using medication abortion. With over twenty years of available data, medication abortion has proven to be remarkably safe and effective. Medication Abortion has only a 0.4% risk of major complications, and a mortality rate of only .00064%. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a .0049% mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the U.S. has an overall maternal mortality rate of .0329%. Medication abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities.
- Technical amendment. In HSC 27051 (b): delete “mifepristone or misoprostol” and insert “brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state.”
SUPPORT AND OPPOSITION:
Support: All Above All (co-sponsor)
Attorney General Rob Bonta (co-sponsor)
Black Women for Wellness Action Project (co-sponsor)
California Commission on Status of Women and Girls (co-sponsor)
California Latinas for Reproductive Justice (co-sponsor)
Essential Health Access (co-sponsor)
National Health Law Program (co-sponsor)
Planned Parenthood Affiliates of California (co-sponsor)
Reproductive Freedom for All California (co-sponsor)
American College of Obstetricians & Gynecologists- District IX
California Civil Liberties Advocacy
California Medical Association
California Nurse Midwives Association
California Primary Care Association Advocates
California Teachers Association
Citizens for Choice
County of Los Angeles
Equality California
NextGen California
Osteopathic Medical Board of California
San Francisco Bay Area Black & Jewish Coalition
One individual
Oppose: None received
-- END --
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: AB 54
AUTHOR: | Krell, Aguiar-Curry | ||
VERSION: | March 17, 2025 | ||
HEARING DATE: | June 11, 2025 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Access to Safe Abortion Care Act
SUMMARY:
Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020.
Existing law:
- Establishes the Reproductive Privacy Act (RPA), which prohibits the state from denying or interfering with a woman’s right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the woman. [HSC §123460, et seq.]
- Prohibits a person who aids or assists a pregnant person in exercising their rights under RPA from being subject to civil or criminal liability or penalty, or otherwise being deprived of their rights, based solely on their actions to aid or assist a pregnant person in exercising their rights under RPA with the pregnant person's voluntary consent. [HSC §123467]
- Provides that a law of another state that authorizes a person to bring a civil action against a person or entity who does any of the following is contrary to the public policy of this state: receives or seeks an abortion; performs or induces an abortion; knowingly engages in conduct that aids or abets the performance or inducement of an abortion; or, attempts or intends to engage in the aforementioned conduct. [HSC §123467.5]
This bill:
- Prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol after January 1, 2020, in accordance with state laws, applicable and accepted standards of care, and good faith compliance with this bill. Requires this bill to be applied retroactively to January 1, 2020.
- States that, consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
- Makes this bill’s provisions severable: if any provision or its application is held invalid, that invalidity is prohibited from affecting other provisions or applications that can be given effect without the invalid provision or application.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, there are no state costs associated with this bill.
PRIOR VOTES:
Assembly Floor: | 61 - 10 |
Assembly Appropriations Committee: Assembly Judiciary Committee | 11 - 1 8 - 1 |
Assembly Health Committee: | 12 - 0 |
COMMENTS:
- Author’s statement. According to the author, in 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. As former Chief Legal Counsel to Planned Parenthood, I fought federal efforts to eliminate access to reproductive care in the first Trump Administration. It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. This bill shields manufacturers, distributers, and health care providers from liability for providing medication abortion to Californians.
- Abortion. According to the Center for Diseases Control and Prevention (CDC), a legal induced abortion is defined as an intervention performed by a licensed clinician that is intended to terminate an ongoing pregnancy. Ending a pregnancy with medications is an option for women who are less than ten weeks pregnant and would like to have an abortion at home with a less invasive procedure. The CDC reports that 613,383 abortions were reported nationally from 48 reporting areas in 2022. From 2021 to 2022, the total number of abortions decreased 2%, and the number decreased 5% between 2013 and 2022. In 2022, women in their 20s accounted for more than half of abortions (56.5%). By contrast, adolescents under 15 years (0.2%) and women over 40 (3.6%) years accounted for the lowest percentages of abortions. In 2022, nearly all abortions (92.8%) were performed at or less than 13 weeks gestation. That year, the highest proportion of abortions were performed by early medication abortion at or less than nine weeks’ gestation (53.3%), followed by surgical abortion at or less than 13 weeks gestation (35.5%), surgical abortion at more than 13 weeks gestation (6.9%), and medication abortion at more than nine weeks gestation (4.3%). In 2021, the most recent year for which data was reviewed for pregnancy-related deaths, five women died as a result of complications from legal induced abortion.
- California data. According to the Guttmacher Institute, 182,170 abortions were provided by clinicians in California in 2024, though not all those abortions were provided to state residents. In January 2025, there were an estimated 17,020 clinician-provided abortions, and that number was consistent with the previous six-month period (average of 15,000 abortions per month). Data for 2023, the first full year after the U.S. Supreme Court overturned Roe v. Wade, show that an estimated total of 179,120 clinician-provided abortions took place in California (an increase of 1.7%).
- Medication abortion. According to a March 2024 Kaiser Family Foundation factsheet, medication abortion is a pregnancy termination protocol that involves taking two different drugs approved for use up to the first 10 weeks of pregnancy by the U.S. Food and Drug Administration (FDA). The World Health Organization has authorized use up to 12 weeks of pregnancy. Since the FDA first approved the drug in 2000, its use in the U.S. has grown. In 2023, 63% of abortions in the U.S. were medication abortions. The most common medication abortion regimen involves the use of two different medications: mifepristone and misoprostol. Mifepristone, also known as the abortion pill or RU-486, is sold under the brand name Mifeprex and through a generic manufactured by GenBioPro. Mifepristone works by blocking progesterone, a hormone essential to the development of a pregnancy, and prevents an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. A follow-up visit can be scheduled a week or two later to confirm that the pregnancy was terminated via ultrasound or blood test. The FDA has found that medication abortion is a safe and highly effective method of pregnancy termination. Medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and a mortality rate of 0.00064%. Telehealth can be used to expand access to abortion services in areas where the number of clinicians who provide that care is limited. Many patients, particularly those who live in rural communities, must travel long distances to obtain abortion services even in states where abortion is still permitted. Because the updated FDA label now allows for telehealth, mifepristone has emerged as an option for patients who are either unable to travel to clinic or for other reasons wish to have an abortion in the privacy of their own home. As part of efforts to limit abortion access, some states have taken action to block the use of telehealth for abortion. Among the states that have not banned abortion, 13 states have at least one restriction that requires at least one trip to the clinic, and effectively ban telehealth for medication abortion.
- Post-Dobbs v. Jackson Women’s Health Organization (2022). According to the Guttmacher Institute website (and as of May 28, 2025), since the Supreme Court overturned Roe v. Wade, 13 states are enforcing a near-total ban on abortion with very limited exceptions (Alabama, Arkansas, Idaho, Indiana, Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, South Dakota, Tennessee, Texas, and West Virginia). In other states, less restrictive rules are in place and include: abortion being banned after six weeks (Florida, Georgia, Iowa, and South Carolina); a 12-week ban (Nebraska and North Carolina); and, an 18-23 week ban (Kansas, Ohio, Utah, and Wisconsin). In Texas and Oklahoma, mailing abortion pills is also banned and criminal or civil liability to providers who mail abortion pills can be assigned. In Louisiana, medication abortion can only be dispensed in person.
According to a February 16, 2023 story in the New York Times, one commonality among many of the bans is that enforcement is enhanced through the targeting of medical providers. For example, in Texas it is a felony to perform an abortion, unless it is needed to save the life of the patient, and provides for civil liability and licensure revocation. The Texas law also provides that any person, other than an officer or employee of a state or local governmental entity in Texas, and regardless if they suffered any actual harm, may bring a civil action to enforce its provisions, which includes liability of $10,000 plus costs and fees if a plaintiff prevails while a defendant is prohibited from recovering their own costs and fees if they prevail. Idaho enacted a similar law, which provides for liability of $20,000 plus costs and fees if a plaintiff prevails. Oklahoma also enacted a similar law to Texas’ and enacted criminal penalties for the performance of an abortion, except when performed to save the life of a pregnant person, with punishment of up to ten years in prison or fines of up to $100,000.
In January 2025, a New York physician was indicted in Louisiana for providing medication abortion across state lines. According to a March 19, 2025 NPR report, Dr. Margaret Carpenter was charged alongside a Louisiana mother who allegedly received the mailed package and gave the pills prescribed by Carpenter to her minor daughter. The teen wanted to keep the pregnancy and called 911 after taking the pills, according to an NPR interview with the Louisiana district attorney prosecuting the case. The charges carry a possible five-year prison sentence. On February 11, Louisiana's governor signed an extradition warrant for Carpenter. He later posted a video arguing she "must face extradition to Louisiana, where she can stand trial and justice will be served." New York's governor countered by releasing her own video, confirming she was refusing to extradite Carpenter. According to a March 27, 2025 AP story, in a separate case involving Dr. Carpenter, a Texas judge ordered her to pay a penalty for allegedly breaking that state's law by prescribing abortion medication via telemedicine. The Texas attorney general's office followed up by asking a New York court to enforce the default civil judgment, which is $113,000 with attorney and filing fees. The acting Ulster County clerk refused, stating, “In accordance with the New York State Shield Law, I have refused this filing and will refuse any similar filings that may come to our office.” According to the March 2025 NPR report, eight states (New York, Maine, California, Colorado, Massachusetts, Rhode Island, Vermont, and Washington) have passed laws since 2022 to protect doctors who mail abortion pills out of state, and thereby block them from extradition in such cases. But the Louisiana case is the first criminal test of these relatively new "shield laws."
- Double referral. This bill has been double referred. Should it pass out of this Committee, it will be referred to the Senate Judiciary Committee.
- Related legislation. AB 40 (Bonta) adds “reproductive health services, including abortion” to the definition of "emergency services and care" in existing law for purposes of provisions requiring hospitals and physicians to provide emergency care to patients without regard to ability to pay. AB 40 is set to be heard in this Committee on June 11, 2025.
AB 260 (Aguiar-Curry), among other provisions: a) permits CDPH to adopt regulations specific to medication abortion drugs, including exempting those drugs from certain requirements if the drugs are no longer approved by the FDA; b) prohibits CDPH from taking criminal, civil, professional discipline, or licensing action against a clinic or health facility for manufacturing, transporting, or engaging in certain acts relating to medication abortion drugs; c) prohibits a health plan contract or a group or individual health insurance policy that covers prescription drugs from limiting or excluding coverage for brand name or generic mifepristone, regardless of its FDA approval status; and, d) requires DHCS to update provider enrollment requirements and procedures for providers who offer reproductive health care services exclusively thorough telehealth. AB 260 is set to be heard in this Committee on June 11, 2025.
- Prior legislation. SB 345 (Skinner, Chapter 260, Statutes of 2023) enacts various safeguards against the enforcement of other states’ laws that prohibit, criminalize, sanction, authorize civil liability against, or otherwise interfere with a person, provider, or other entity in California that offers reproductive health care services or gender-affirming health care services.
SB 487 (Atkins, Chapter 261, Statutes of 2023) prohibits health plans and health insurers from terminating, discriminating against, or otherwise penalizing a provider based on a civil judgment, criminal conviction, or another disciplinary action in another state if the judgment, conviction, or disciplinary action is solely based on the application of another state’s law that interferes with a person’s right to receive care that would be lawful if provided in California.
SB 487 permits the Department of Health Care Services to elect not to suspend a Medi-Cal provider who has a license, certificate, or other approval to provide health care suspended or revoked in another state if the revocation or suspension is based solely on conduct that is not deemed to be unprofessional conduct under California law.
AB 1666 (Bauer-Kahan, Chapter 42, Statutes of 2022) prohibits the enforcement of out-of-state laws authorizing a civil action against a person or entity that receives or performs or induces, or aids or abets the performance of an abortion, or who attempts or intends to engage in those actions and declares those out-of-state laws to be contrary to the public policy of this state.
AB 2091 (Mia Bonta, Chapter 628, Statutes of 2022), among other things, prohibits compelling a person to identify or provide information that would identify an individual who has sought or obtained an abortion in a state, county, city, or other local criminal, administrative, legislative, or other proceeding if the information is being requested based on another state’s laws that interfere with a person’s right to choose or obtain an abortion or a foreign penal civil action.
AB 2223 (Wicks, Chapter 629, Statutes of 2022) prohibits a person from being subject to civil or criminal liability, or otherwise deprived of their rights, based on their actions or omissions with respect to their pregnancy or actual, potential, or alleged pregnancy outcome or based solely on their actions to aid or assist a pregnant person who is exercising their reproductive rights.
SB 1301 (Kuehl, Chapter 385, Statutes of 2002) enacts the RPA, which provides that every individual possesses a fundamental right of privacy with respect to reproductive decisions, including the fundamental right to choose or refuse birth control, and the fundamental right to choose to bear a child or obtain an abortion.
- Support. The sponsors of this bill write that with over 20 years of available data, medication abortion has proven to be remarkably safe and effective. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. This bill will preserve the constitutional and statutory right to choose and obtain abortions in the state of California by ensuring there is sufficient access to medication abortion and the ability to facilitate access. Additionally, this bill shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering medication abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance. Sponsors further state that providers and researchers estimate that over 60% of all abortions in the U.S. are done using medication abortion. With over twenty years of available data, medication abortion has proven to be remarkably safe and effective. Medication Abortion has only a 0.4% risk of major complications, and a mortality rate of only .00064%. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a .0049% mortality rate. Using medication abortion is also far safer than carrying a pregnancy to term, as the U.S. has an overall maternal mortality rate of .0329%. Medication abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities.
- Technical amendment. In HSC 27051 (b): delete “mifepristone or misoprostol” and insert “brand name or generic mifepristone or any drug used for medication abortion that is lawful under the laws of the state.”
SUPPORT AND OPPOSITION:
Support: All Above All (co-sponsor)
Attorney General Rob Bonta (co-sponsor)
Black Women for Wellness Action Project (co-sponsor)
California Commission on Status of Women and Girls (co-sponsor)
California Latinas for Reproductive Justice (co-sponsor)
Essential Health Access (co-sponsor)
National Health Law Program (co-sponsor)
Planned Parenthood Affiliates of California (co-sponsor)
Reproductive Freedom for All California (co-sponsor)
American College of Obstetricians & Gynecologists- District IX
California Civil Liberties Advocacy
California Medical Association
California Nurse Midwives Association
California Primary Care Association Advocates
California Teachers Association
Citizens for Choice
County of Los Angeles
Equality California
NextGen California
Osteopathic Medical Board of California
San Francisco Bay Area Black & Jewish Coalition
One individual
Oppose: None received
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 54
Author:(Krell and Aguiar-Curry)
As Amended Ver:March 17, 2025
Majority vote
SUMMARY
Establishes the Access to Safe Abortion Care Act, which prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance with the provisions of this bill.
Major Provisions
COMMENTS
Medication Abortion. According to a March 20, 2024 Kaiser Family Foundation (KFF) issue brief, ″The Availability and Use of Medication Abortion,″ medication abortion, also known as medical abortion or abortion with pills, is a pregnancy termination protocol that involves taking two different drugs: mifepristone and misoprostol. Mifepristone, also known as the abortion pill, or RU-486 is sold under the brand name Mifeprex and through a generic manufactured by GenBioPro in the United States. Mifepristone works by blocking progesterone, a hormone essential to the development of a pregnancy, and thereby preventing an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. A follow-up visit can be scheduled a week or two later, to confirm that the pregnancy was terminated via ultrasound or blood test. The federal Food and Drug Administration (FDA) has found that medication abortion is a safe and highly effective method of pregnancy termination. When taken, medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and an associated mortality rate of less than 0.001% (0.00064%).
The FDA first approved Mifeprex in 2000. In 2016, the FDA updated and approved a new evidence-based regimen and drug label. This regimen approves use of medical abortions for up to 70 days (10 weeks) of pregnancy. Until 2019, mifepristone was only sold under the brand name Mifeprex, manufactured by Danco Laboratories. In 2019, the FDA approved GenBioPro, Inc.′s application for generic mifepristone. In 2021, the FDA announced they would not enforce the in-person dispensing requirement that had been in effect since the approval of mifepristone.
Abortion Access. Even before the overturn of Roe v. Wade in 2022, abortion access has been under attack. The Dobbs v. Jackson Women′s Health Organization decision, coupled with a federal administration hostile to reproductive health access creates new and emerging legal threats to access, even in California. For instance, a pending lawsuit challenges the FDA′s approval of mifepristone (Missouri et al. v. FDA; Alliance for Hippocratic Medicine v. FDA) and Texas has sued a New York healthcare provider for proscribing abortion pills to a patient. This bill proposes to protect access to medication abortion for Californians by shielding the transporting, distributing, and administering of this vital and safe product.
Access to medication abortion plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. According to the Guttmacher Institute, 60% of individuals who seek abortions are people of color, and half live below the poverty line. Communities of color continue to get worse medical care overall, including worse reproductive health care with less access to contraception, and are more likely to be uninsured than white individuals. About 19% of American Indian and Alaska Native communities and about 18% of Hispanic or Latino people are uninsured, compared with less than 6% of non-Hispanic white people. Therefore, making access to reproductive care is an equity issue, and especially critical for underserved communities.
According to the Author
In 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state′s constitution. The author states that as California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. The author notes that as former Chief Legal Counsel to Planned Parenthood, she fought federal efforts to eliminate access to reproductive care in the first Trump Administration, and that it is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. The author concludes that this bill shields manufacturers, distributers, and health care provides from liability for providing medication abortion to Californians.
Arguments in Support
Attorney General Rob Bonta is the sponsor of this bill and states that Medication Abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. The Attorney General notes that there are emerging threats to the availability of Medication Abortion, and we must do everything we can to ensure Californians continue to have access to this critical medication. This bill will continue to safeguard the constitutional and statutory right to choose and obtain abortions in California by ensuring there is sufficient access to Medication Abortion. The Attorney General concludes that this bill shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering Medication Abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance.
Arguments in Opposition
None on file
FISCAL COMMENTS
According to the Assembly Appropriations Committee, there are no state costs associated with this bill.
VOTES
ASM HEALTH: 12-0-3
YES: Bonta, Addis, Aguiar-Curry, Arambula, Carrillo, Mark González, Krell, Patel, Celeste Rodriguez, Schiavo, Sharp-Collins, Stefani
ABS, ABST OR NV: Chen, Flora, Sanchez
ASM JUDICIARY: 8-1-3
YES: Kalra, Bryan, Connolly, Harabedian, Pacheco, Papan, Stefani, Zbur
NO: Macedo
ABS, ABST OR NV: Dixon, Bauer-Kahan, Sanchez
ASM APPROPRIATIONS: 11-1-3
YES: Wicks, Arambula, Calderon, Caloza, Elhawary, Fong, Mark González, Hart, Pacheco, Pellerin, Solache
NO: Ta
ABS, ABST OR NV: Sanchez, Dixon, Tangipa
UPDATED
VERSION: March 17, 2025
CONSULTANT: Lara Flynn / HEALTH / (916) 319-2097 FN: 0000350
Date of Hearing: May 7, 2025
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 54
Author:(Krell) – As Amended Ver:March 17, 2025
Policy Committee: | Health | Vote: | 12 - 0 |
Judiciary | 8 - 1 | ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill establishes the Access to Safe Abortion Care Act, reaffirming that it has been, and will continue to be, lawful to transport or receive any drug, medicine, or instrument that can be designated or adapted to produce a lawful abortion in California.
Specifically, this bill:
- Prohibits the imposition of criminal or civil liability, or professional disciplinary action, against a manufacturer, distributor, authorized health care provider, pharmacist, or individual for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance. Provides that this provision applies retroactively.
- Makes findings and declarations about the constitutional right to access reproductive health services in this state and noting, among other things, that the widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the state, including safeguarding the health and welfare of Californians.
- Makes the provisions of this bill severable.
FISCAL EFFECT:
No state costs.
COMMENTS:
This bill is sponsored by Attorney General Rob Bonta, Planned Parenthood Affiliates of California, Black Women for Wellness Action Project, Reproductive Freedom for All California, California Latinas for Reproductive Justice, All* Above All, National Health Law Program, Essential Access Health, and the California Commission on Status of Women and Girls.
According to the author:
Access to medication abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. Restricted reproductive access can lead to increased healthcare costs (unplanned pregnancies, travel/accommodations, late-term birth complications) and economic hardship, impacting communities, while expanded access can improve overall health outcomes and reduce long-term healthcare burdens.
In 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states…It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. AB 54 shields manufacturers, distributers, and health care providers from liability for providing medication abortion to Californians.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 29, 2025
ASSEMBLY COMMITTEE ON JUDICIARY
Ash Kalra, Chair
ABPCA Bill Id:AB 54
Author:(Krell) – As Amended Ver:March 17, 2025
SUBJECT: Access to Safe Abortion Care Act
KEY ISSUE: should the legislature reaffirm the state of California’s commitment to provide safe and accessible reproductive health care services for all residents?
SYNOPSIS
The United States Supreme Court’s decision in Dobbs v. Jackson Women’s Health Org. (2022) 141 S. Ct. 2619, represented the first time the Court has ever revoked a previously held constitutional right. In the wake of that radical decision, dozens of states have moved to prohibit abortion and enact a series of draconian measures seeking to punish those who seek safe and reliable healthcare in other states. The newly restored Trump Administration, in order to mollify the desires of its political base, is seeking to further limit access to safe and reliable healthcare and is directly seeking to undermine the protections provided by states like California.
This bill would reaffirm California’s commitment to providing safe access to reproductive healthcare. First, this measure adopts a series of findings that state the Legislature’s ongoing commitment to protect reproductive freedom in this state. Secondly, the bill clarifies that no healthcare professional can be held criminally or civilly liable for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol, the two drugs critical to providing medication abortion.
This important measure is sponsored by Attorney General Rob Bonta and is supported by a coalition of reproductive healthcare advocates. The proponents highlight the need to reaffirm California’s commitment to safe and effective reproductive health services. This measure has no known opposition and was previously heard and approved by the Committee on Health by a vote of 12 to 0.
SUMMARY: Reaffirms that it is lawful in the State of California to deliver, or mail, ship, take, receive, or otherwise transport, any drug, medicine, or instrument that can be designed or adapted to produce an abortion. Specifically, this bill:
- States that it is consistent with the public policy and constitutional guarantees of California, and to avoid any confusion or misinformation on the matter, that the Legislature reaffirms that it has been, and shall continue to be, lawful to cause the delivery of, or mail, ship, take, receive, or otherwise transport, into California from out of state or within the boundaries of California, any drug, medicine, or instrument that can be designed or adapted to produce an abortion that is lawful in the State of California.
- Prohibits the imposition of criminal or civil liability, as well as professional discipline, against a manufacturer, distributor, authorized health care provider, pharmacist, or individual for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith.
- Makes various findings and declarations about the constitutional right to access reproductive health services in this state.
- Adopts a severability clause.
EXISTING LAW:
- Prohibits the state from denying or interfering with an individual’s reproductive freedom in their most intimate decisions, which includes their fundamental right to choose to have an abortion and their fundamental right to choose or refuse contraceptives. (Cal. Const. art I, Sec. 1.1,)
- Establishes the Reproductive Privacy Act and declares that every individual possesses a fundamental right of privacy with respect to personal reproductive decisions, which entails the right to make and effectuate decisions about all matters relating to pregnancy, including prenatal care, childbirth, postpartum care, contraception, sterilization, abortion care, miscarriage management, and infertility care. (Health and Safety Code Section 123460 et seq.)
- Prohibits the state from denying or interfering with a pregnant person’s right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the woman or pregnant person. (Health and Safety Code Section 123466 (a).)
- Defines for the purpose of 3) “state” to mean the State of California, and every county, city, town and municipal corporation, and quasi-municipal corporation in the state. (Health and Safety Code Section 123464 (c).)
- Declares that laws from other states authorizing civil actions against individuals involved in abortion-related activities are contrary to the public policy of the state and prohibits their application in state court, and bars the enforcement of civil judgments based on such laws. (Health and Safety Code Section 123467.5.)
- Prohibits licensing boards from disciplining healthcare providers based on out-of-state judgments related to sensitive services, including reproductive or gender-affirming healthcare, protects personal information at family planning centers, and blocks enforcement of certain out-of-state laws against individuals or providers offering such services. (Business and Professions Code Section 852.)
FISCAL EFFECT: As currently in print this bill is keyed fiscal.
COMMENTS: To the nearly 40 million Americans that call California home, this state has long been a bastion of freedom, a state with a history of respecting individualism, uniqueness, and the liberty to be one’s self. Unfortunately, for large parts of the past decade, the rest of the United States has targeted the values many Californians hold dear. As a part of America’s endless culture wars, many of the rights and privileges provided to California residents have been deemed “un-American” by those outside of this state. One such value has been California’s long-held respect for the freedom of one’s right to choose what to do with their own body. Indeed, following the United States Supreme Court’s revocation of the federally recognized right to abortion and other reproductive health services (Dobbs v. Jackson Women’s Health Organization (2022) 597 U.S. 215), the current federal administration is taking aim at reproductive freedom across the country. This bill would reaffirm California’s commitment to reproductive freedom, including the right to receive the medications necessary to facilitate an abortion. In support of this critical bill to reaffirm California’s values, the author states:
In 2022 California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. As California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. As former Chief Legal Counsel to Planned Parenthood, I fought federal efforts to eliminate access to reproductive care in the first Trump Administration. It is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. AB 54 shields manufacturers, distributers, and health care provides from liability for providing medication abortion to Californians.
A series of draconian laws in other states and new actions by the federal government seek to limit medical professional’s ability to provide vital reproductive healthcare. Following the United States Supreme Court’s unprecedented decision to eliminate a previously held constitutional right and determine that no right to an abortion exists under the United States Constitution (Dobbs v. Jackson Women’s Health Organization, supra), access to abortion care is now determined on a state-by-state basis. Since Dobbs, 16 states have moved to effectively ban abortion. (https://states.guttmacher.org/policies.) Even more troubling, many of these states are now trying to target out-of-state medical providers who give care to their residents, even if the out-of-state resident comes to California to receive care that is entirely legal within this jurisdiction.
Although California has become a safe haven for persons seeking medical treatment, the fact that medical professionals are being targeted by other states can have implications in California. For example, should a California-based doctor have a license in a jurisdiction that now prohibits abortion, and a woman from that state travels to California and receives care from the doctor, the doctor may be subject to discipline from the other state’s medical regulator for violating the other state’s laws. To better protect California’s medical professionals, in 2023, the Legislature enacted SB 345 (Skinner) Chap. 260, Stats. 2023, to safeguard the professional licenses of California healthcare providers who may draw the ire of out-of-state authorities.
Despite these protections, upon reassuming power, the Trump Administration is targeting access to safe abortion services nationwide. Although the current Secretary of Health and Human services appears to be far more interested in minimizing and spreading misinformation about vaccines and the ongoing measles outbreak plaguing several southern states than limiting abortion access (Amanda Seitz, RFK Jr.'s mixed message about the measles outbreaks draws criticism from health officials, The Associated Press (Apr. 16, 2025), available at: https://apnews.com/article/measles-outbreak-rfk-jr-messaging-criticism-vaccine-1a2cbdc14eb0c256695fdfac00cbfb6d.), the administration has made it clear that it eventually will seek to limit access to abortion drugs like mifepristone. (Berkeley Lovelace Jr., Trump's FDA pick says he'll review whether abortion pill must be dispensed in person again, NBC News (Mar. 6, 2025), available at: https://www.nbcnews.com/health/health-news/trumps-fda-pick-says-review-whether-abortion-pill-must-dispensed-perso-rcna195156.)
Medication abortion has proven to be safe and effective for over 20 years. When abortion was first permitted in the United States, the procedure required a patient to come to a clinic to receive treatment. However, in the early 2000s, the pill RU-486 (also known as mifepristone) became available in the United States. Taken in conjunction with the drug misoprostol, these two drugs induce a “medication abortion” by blocking progesterone, a hormone essential to the development of a pregnancy, and thereby prevent an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. If necessary, a follow-up appointment with the pregnant person’s physician can be scheduled to confirm that the pregnancy was terminated. The federal Food and Drug Administration has found that medication abortion is a safe and highly effective method of ending a pregnancy. When taken, medication abortion successfully terminates the pregnancy 99.6% of the time, with only a 0.4% risk of major complications, and an associated mortality rate of less than 0.001 percent (0.00064%).
This bill protects Californians access to reproductive health services, including mifepristone. This bill seeks to protect access to reproductive health services in California by clarifying that a manufacturer, distributor, authorized health care provider, pharmacist, or individual cannot be subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol on or after January 1, 2020. The bill makes numerous findings and declarations regarding the importance of reproductive healthcare and reaffirms the state’s commitment to safe access to abortion services.
ARGUMENTS IN SUPPORT: This bill is sponsored by Attorney General Rob Bonta and is supported by a coalition of reproductive health advocates. In support of the bill, the Attorney General writes:
In 2000, the Food and Drug Administration approved mifepristone for use in the termination of pregnancy. Mifepristone can be used on its own to terminate a pregnancy, but it’s usually used in combination with a second drug, Misoprostol. When Mifepristone and Misoprostol are used in combination, or when Misoprostol is used alone to terminate a pregnancy, this is referred to as a “Medication Abortion,” to distinguish it from a procedural abortion. Today, providers and researchers estimate that over 60% of all abortions in the United States are done using Medication Abortion. With over twenty years of available data, Medication Abortion has proven to be remarkably safe and effective. Medication Abortion has only a 0.4% risk of major complications, and a mortality rate of only .00064%. To put these figures in perspective, this is lower than the mortality rate associated with Viagra, which carries a .0049% mortality rate. Using Medication Abortion is also far safer than carrying a pregnancy to term, as the U.S. has an overall maternal mortality rate of .0329%.
There are emerging threats to the availability of Medication Abortion, and we must do everything we can to ensure Californians continue to have access to this critical medication.
AB 54 will continue to safeguard the constitutional and statutory right to choose and obtain abortions in California by ensuring there is sufficient access to Medication Abortion. Additionally, AB 54 shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering Medication Abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance.
REGISTERED SUPPORT / OPPOSITION:
Support
Attorney General Rob Bonta (sponsor)
All Above All
Black Women for Wellness Action Project
California Latinas for Reproductive Justice
California Teachers Association
Essential Access Health
National Health Law Program
Planned Parenthood Affiliates of California
Reproductive Freedom for All California
Opposition
None on file
Analysis Prepared by: Nicholas Liedtke / JUD. / (916) 319-2334
Date of Hearing: April 8, 2025
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 54
Author:(Krell) – As Amended Ver:March 17, 2025
SUBJECT: Access to Safe Abortion Care Act.
SUMMARY: Establishes the Access to Safe Abortion Care Act, which prohibits a manufacturer, distributor, authorized health care provider, pharmacist, or individual from being subject to civil or criminal liability, or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, dispensing, or administering mifepristone or misoprostol on or after January 1, 2020, in accordance with the laws of this state, applicable and accepted standards of care, and good faith compliance with the provisions of this bill. Specifically, this bill:
- Makes various findings and declarations noting that the widespread availability of mifepristone and misoprostol, through both state instrumentalities and private actors, furthers the policies and goals of the State of California, including safeguarding the health and welfare of Californians — as a safe, effective, and accessible means of terminating a pregnancy, and by providing medical providers with safe and effective options to treat their patients under a wide variety of circumstances.
- Makes the provisions of this bill severable. States that if any provision of this bill or its application is held invalid, that invalidity does not affect other provisions or applications that can be given effect without the invalid provision or application.
EXISTING LAW:
- Establishes the Reproductive Privacy Act and provides that the Legislature finds and declares that every individual possesses a fundamental right of privacy with respect to personal reproductive decisions and, therefore, it is the public policy of the State of California that:
- Every individual has the fundamental right to choose or refuse birth control; and,
- Every individual has the fundamental right to choose to bear a child or to choose to obtain an abortion, with specified limited exceptions. [Health & Safety Code (HSC) §§ 123460 et seq., 123462 (a)-(b).]
- Prohibits the state from denying or interfering with a person’s right to choose or obtain an abortion prior to viability of the fetus or when the abortion is necessary to protect the life or health of the person. [HSC §§ 123462 (c), 123466.]
- Declares that laws from other states authorizing civil actions against individuals involved in abortion-related activities are contrary to the public policy of the state and prohibits their application in state court, and bars the enforcement of civil judgments based on such laws. [HSC § 123467.5]
- Prohibits licensing boards from disciplining healthcare providers based on out-of-state judgments related to sensitive services like reproductive or gender-affirming healthcare, protects personal information at family planning centers, and blocks enforcement of certain out-of-state laws against individuals or providers offering such services. [Business and Professions Code § 852]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, in 2022, California voters overwhelmingly passed Proposition 1 to enshrine the right to abortion in our state’s constitution. The author states that as California remains a national leader in protecting reproductive rights, attacks on bodily autonomy continue throughout the country. Californians are not on an island, our patients and healthcare providers could be harmed by hostile actions from the federal government and other states. The author notes that as former Chief Legal Counsel to Planned Parenthood, she fought federal efforts to eliminate access to reproductive care in the first Trump Administration, and that it is essential to ensure that the supply chain process from manufacturing, to distribution of medication abortion to a patient is protected in California. The author concludes that this bill shields manufacturers, distributers, and health care provides from liability for providing medication abortion to Californians.
- BACKGROUND.
- Medication Abortion. According to a March 20, 2024 Kaiser Family Foundation (KFF) issue brief, “The Availability and Use of Medication Abortion,” medication abortion, also known as medical abortion or abortion with pills, is a pregnancy termination protocol that involves taking two different drugs: mifepristone and misoprostol. Mifepristone, also known as the abortion pill, or RU-486 is sold under the brand name Mifeprex and through a generic manufactured by GenBioPro in the United States. Mifepristone works by blocking progesterone, a hormone essential to the development of a pregnancy, and thereby preventing an existing pregnancy from progressing. Misoprostol, taken 24 to 48 hours after mifepristone, works to empty the uterus by causing cramping and bleeding, similar to an early miscarriage. A follow-up visit can be scheduled a week or two later, to confirm that the pregnancy was terminated via ultrasound or blood test. The federal Food and Drug Administration (FDA) has found that medication abortion is a safe and highly effective method of pregnancy termination. When taken, medication abortion successfully terminates the pregnancy 99.6% of the time, with a 0.4% risk of major complications, and an associated mortality rate of less than 0.001 percent (0.00064%).
The FDA first approved Mifeprex in 2000. In 2016, the FDA updated and approved a new evidence-based regimen and drug label. This regimen approves use of medical abortions for up to 70 days (10 weeks) of pregnancy. Until 2019, mifepristone was only sold under the brand name Mifeprex, manufactured by Danco Laboratories. In 2019, the FDA approved GenBioPro, Inc.’s application for generic mifepristone. In 2021, the FDA announced they would not enforce the in-person dispensing requirement that had been in effect since the approval of mifepristone.
- Abortion Access. Even before the overturn of Roe v. Wade in 2022, abortion access has been under attack. The Dobbs v. Jackson Women’s Health Organization decision, coupled with a federal administration hostile to reproductive health access creates new and emerging legal threats to access, even in California. For instance, a pending lawsuit challenges the FDA’s approval of mifepristone (Missouri et al. v. FDA; Alliance for Hippocratic Medicine v. FDA) and Texas has sued a NY healthcare provider for proscribing abortion pills to a patient. This bill proposes to protect access to medication abortion for Californians by shielding the transporting, distributing, and administering of this vital and safe product.
Access to medication abortion plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. According to the Guttmacher Institute, 60% of individuals who seek abortions are people of color, and half live below the poverty line. Communities of color continue to get worse medical care overall, including worse reproductive health care with less access to contraception, and are more likely to be uninsured than white individuals. About 19% of American Indian and Alaska Native communities and about 18% of Hispanic or Latino people are uninsured, compared with less than 6% of non-Hispanic white people. Therefore, making access to reproductive care is an equity issue, and especially critical for underserved communities.
- SUPPORT. Attorney General Rob Bonta is the sponsor of this bill and states that Medication Abortion allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive. It plays an important role in reducing barriers and promoting equitable access to healthcare, particularly for those who live in rural and underserved communities. The Attorney General notes that there are emerging threats to the availability of Medication Abortion, and we must do everything we can to ensure Californians continue to have access to this critical medication. This bill will continue to safeguard the constitutional and statutory right to choose and obtain abortions in California by ensuring there is sufficient access to Medication Abortion. The Attorney General concludes that this bill shields manufacturers, distributors, authorized health care providers, or individuals from civil or criminal liability or professional disciplinary action, for accessing, mailing, shipping, receiving, transporting, distributing, or administering Medication Abortion in accordance with the law of this state, applicable and accepted standards of care, and good faith compliance.
- RELATED LEGISLATION.
- AB 40 (Bonta) would clarify in current law that “emergency services and care” includes abortion and other reproductive health services, as necessary to relieve or eliminate an emergency medical condition. Contains an urgency clause to ensure that the provisions of this bill go into immediate effect upon enactment. AB 40 passed the Assembly Health Committee on March 25, 2024, with a vote of 12 to 0 and is currently pending in the Assembly Appropriations Committee.
- AB 67 (Bauer-Kahan) would impose a civil penalty not exceeding $25,000 upon any person or governmental entity that violates any provision of the Reproductive Privacy Act and a civil penalty for violation of the bill’s provisions. The bill would require any costs, fees, and civil penalties collected pursuant to these provisions to be available to the office of the Attorney General upon appropriation of the Legislature for exclusive use by the Attorney General for enforcement of act.
- AB 260 (Aguiar-Curry) would repeal unconstitutional, and delete obsolete provisions of current law relating to criminal abortion penalties. The bill would authorize the California Department of Public Health (DPH) to adopt regulations specific to mifepristone and other medication abortion drugs, including excluding those drugs from certain requirements if the drugs are no longer approved by the United States Food and Drug Administration (FDA). AB 260 would place various requirements on pharmacists related to prescribing and dispensing mifepristone or other medical abortion drugs. Prohibits DPH from taking criminal, civil, professional discipline, or licensing action against a clinic or health facility for manufacturing, transporting, or engaging in certain acts relating to mifepristone or other medication abortion drugs. The bill would also require the Department of Health Care Services (DHCS) to update provider enrollment requirements and procedures for remote service providers who offer reproductive health care services exclusively thorough telehealth modalities. AB 260 would prohibit a health care service plan contract or a group or individual disability insurance policy that covers prescription drugs from limiting or excluding coverage for brand name or generic mifepristone, regardless of its FDA approval status. The bill would also make various changes to requirements specific to healing arts practitioners who are authorized to prescribe, furnish, order, or administer certain drugs. AB 260 is pending in the Assembly Health Committee.
- AB 290 (Bauer-Kahan) would increase the fine for a hospital’s failure to adopt the policies and protocols required for the provision of emergency services and care from $1,000 a day to $1,000,000 per day. AB 290 is currently pending in the Assembly Health Committee.
- AB 551 (Krell) would, upon appropriation by the Legislature or the availability of funds from private sources, establish the Reproductive Health Emergency Preparedness Program (RHEPP) for the purpose of expanding and improving access to reproductive and sexual health care in emergency departments across California. AB 551 is currently pending in the Assembly Health Committee.
- AB 1500 (Schiavo) would require the State Department of Public Health (DPH) to partner with an organization, as specified, to update and maintain the Abortion.gov internet website. The bill would also require the internet website to include additional information on sexual and reproductive health, including, among others, sexual and reproductive health information historically relied on and made available on federal internet websites, as specified.
- PREVIOUS LEGISLATION.
- AB 1666 (Bauer Kahan), Chapter 42, Statutes of 2022 declared that laws from other states authorizing civil actions against individuals involved in abortion-related activities are contrary to the public policy of the state and prohibits their application in state court, and bars the enforcement of civil judgments based on such laws.
- SB 345 (Skinner), Chapter 260, Statutes of 2023 prohibits licensing boards from disciplining healthcare providers based on out-of-state judgments related to sensitive services like reproductive or gender-affirming healthcare, protects personal information at family planning centers, and blocks enforcement of certain out-of-state laws against individuals or providers offering such services. It also provides civil remedies for abusive litigation, bars certain cooperation with investigations from other states, and imposes penalties on individuals who apprehend or arrest people for violating out-of-state reproductive or gender-affirming healthcare laws.
- AB 1918 (Petrie-Norris), Chapter 561, Statutes of 2022, establishes the California Reproductive Health Service Corps program within HCAI to reduce the debt burden of current and future health care professionals dedicated to providing reproductive health care in underserved areas of California.
- AB 2091 (Mia Bonta), Chapter 628, Statutes of 2022, prohibits compelling a person to identify or provide information that would identify an individual who has sought or obtained an abortion in a state, county, city, or other local criminal, administrative, legislative, or other proceeding.
- AB 2134 (Akilah Weber), Chapter 562, Statutes of 2022, establishes the California Reproductive Health Equity Program within HCAI to ensure abortion and contraception services are affordable for and accessible to all patients and to provide financial support for safety net providers of these services.
- AB 2223 (Wicks), Chapter 629, Statutes of 2022, prohibits a person from being subject to civil or criminal liability, or otherwise deprived of their rights, based on their actions or omissions with respect to their pregnancy or actual, potential, or alleged pregnancy outcome or based solely on their actions to aid or assist a pregnant person who is exercising their reproductive rights.
- SB 1301 (Sheila Kuehl), Chapter 385, Statutes of 2002, enacts the Reproductive Privacy Act, which provides that every individual possesses a fundamental right of privacy with respect to reproductive decisions, including the fundamental right to choose or refuse birth control, and the fundamental right to choose to bear a child or obtain an abortion.
6) DOUBLE REFERRAL. This bill is double referred. Upon passage of this committee, it will be referred to the Assembly Judiciary Committee.
REGISTERED SUPPORT / OPPOSITION:
Support
Attorney General Rob Bonta
All Above All
California Latinas for Reproductive Justice
National Health Law Program
Planned Parenthood Affiliates of California
Reproductive Freedom for All California
Opposition
Four individuals
Analysis Prepared by: Lara Flynn / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):